

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/002529

International filing date: 10 March 2005 (10.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: EP  
Number: 04007020.3  
Filing date: 24 March 2004 (24.03.2004)

Date of receipt at the International Bureau: 06 April 2005 (06.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



**Europäisches  
Patentamt**

**European  
Patent Office**

**Office européen  
des brevets**

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

**Patentanmeldung Nr. Patent application No. Demande de brevet n°**

04007020.3

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

**R C van Dijk**





Anmeldung Nr:  
Application no.: 04007020.3  
Demande no:

Anmeldetag:  
Date of filing: 24.03.04  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Bayer Health Care Aktiengesellschaft  
Kaiser-Wilhelm-Allee  
51373 Leverkusen  
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

Diagnostics and therapeutics for diseases associated with peroxisome proliferator  
activated receptor delta (PPARD)

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

G01N33/48

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PL PT RO SE SI SK TR LI





24. März 2004

- 1 -

**Diagnostics and Therapeutics for Diseases Associated with Peroxisome Proliferator Activated Receptor Delta (PPARD)**

**Technical field of the invention**

The present invention is in the field of molecular biology, more particularly, the present invention  
5 relates to nucleic acid sequences and amino acid sequences of a human PPARD and its regulation for the treatment of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in mammals.

**Background of the invention**

10 **Nuclear Receptors**

PPARD belongs to the superfamily of nuclear receptors (NR) [[Robinson-Rechavi et al., 2003],  
[Schmidt et al. (1992)], [Kersten et al. (2000)], US 6689574, WO02064632] which forms a related  
but diverse array of ligand-modulated transcription factors that control diverse aspects of growth,  
development and homeostasis [Olefsky & Jerrold, 2001]. The family comprises the nuclear  
15 hormone receptors for which hormonal ligands have been identified, and orphan receptors with  
still unknown ligands.

The ligands of NRs are generally lipophilic because they traverse the plasma membrane to bind to  
their cognate receptors that are located in the cytoplasm or in the nucleus.

Six structural domains A-F (from N- to C-terminus) of NR are known [Bourguet et al. 2000]. All  
20 of the NRs have common structural features which include a central DNA binding domain (DBD,  
domain C) responsible for targeting the receptor to a specific DNA sequence, a ligand binding  
domain (LBD, domain E), that binds to specific ligands and activates transcription and a hinge  
region (domain D) connecting DBD and LBD. The N-terminus is formed by the A/B domain  
comprising a ligand-independent activation domain. The C-terminal F domain, the function of  
25 which is poorly understood, is not present in all receptors.

NRs activate transcription as homo- or heterodimers by binding to specific response elements  
(REs). The REs exist of two half-sites with different spacings, forming inverted or direct repeats.  
Based on their mode of action four different classes of NRs have been defined: class 1 is formed  
by the known steroid hormone receptors, that act as homodimers and bind to inverted repeats; class  
30 2 includes receptors forming heterodimers with RXR; class 3 contains homodimeric NRs binding

to direct repeats and class 4 is formed by NRs that bind as monomers to single half-sites. Classes 3 and 4 contain only orphan receptors.

NRs act as transcription activators in complex with co-activators. Ligand binding to NRs induces a conformational change which allows recruitment of specific co-activators. In the absence of ligand  
5 some receptors also act as transcriptional repressors in complex with co-repressors.

The fact that steroid hormone receptors belong to the family of nuclear receptors indicates that these receptors have an established, proven history as therapeutic targets. Examples for marketed pharmaceuticals based on steroid receptor ligands comprise preparations containing oestrogens, corticosteroids or mineralocorticoids. Clearly, there is a need for identification and charac-  
10 terization of further receptors which can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, cancers, allergies including asthma, cardiovascular diseases including acute heart failure, hypotension, hypertension, angina pectoris, myocardial infarction, hematological diseases, genito-urinary diseases including  
15 urinary incontinence and benign prostate hyperplasia, osteoporosis, peripheral and central nervous system disorders including pain, Alzheimer's disease and Parkinson's disease, respiratory diseases, metabolic diseases, inflammatory diseases, gastro-enterological diseases, diseases of the endocrine system, dermatological diseases, diseases of muscles or the skeleton, immunological diseases, developmental diseases or diseases of the reproductive system.

## 20 **TaqMan-Technology / expression profiling**

TaqMan is a recently developed technique, in which the release of a fluorescent reporter dye from a hybridisation probe in real-time during a polymerase chain reaction (PCR) is proportional to the accumulation of the PCR product. Quantification is based on the early, linear part of the reaction, and by determining the threshold cycle (CT), at which fluorescence above background is first  
25 detected.

Gene expression technologies may be useful in several areas of drug discovery and development, such as target identification, lead optimization, and identification of mechanisms of action. The TaqMan technology can be used to compare differences between expression profiles of normal tissue and diseased tissue. Expression profiling has been used in identifying genes, which are up-  
30 or downregulated in a variety of diseases. An interesting application of expression profiling is temporal monitoring of changes in gene expression during disease progression and drug treatment or in patients versus healthy individuals. The premise in this approach is that changes in pattern of gene expression in response to physiological or environmental stimuli (e.g., drugs) may serve as

indirect clues about disease-causing genes or drug targets. Moreover, the effects of drugs with established efficacy on global gene expression patterns may provide a guidepost, or a genetic signature, against which a new drug candidate can be compared.

### **PPARD**

- 5 The nucleotide sequence of PPARD is accessible in the databases by the accession number L07592 and is given in SEQ ID NO: 1. The amino acid sequence of PPARD depicted in SEQ ID NO: 2.

Nuclear hormone receptors form one evolutionary related super-family of proteins, which mediate the interaction between hormones (or other ligands) and gene expression in animals. Early phylogenetic analyses showed two main periods of gene duplication which gave rise to present-day  
10 diversity in most animals: one at the origin of the family, and another specifically in vertebrates. Moreover this second period is composed itself by, probably, two rounds of duplication at the origin of vertebrates. There are indeed often two, three or four vertebrate orthologs of each invertebrate nuclear receptor, in accordance with this theory. The complete genome of *Drosophila melanogaster* contains 21 nuclear receptors, compared to 49 in the human genome [Robinson-  
15 Rechavi et al., 2003].

By cDNA cloning from a human osteosarcoma cell library, Schmidt et al. [Schmidt et al. (1992)] identified a novel member of PPAR superfamily, PPARD, which they called NUC1 (or NUC1), that is predicted to encode a 441-amino acid protein. Northern blot analysis with rat PPARD RNA showed highest expression in heart, kidney, and lung. The protein was shown to be experimentally  
20 activated by arachidonic and oleic acids as well as the peroxisome proliferator activator WY14643.

Kersten et al. [Kersten et al. (2000)] reviewed the roles of PPARs in health and disease.

PPARD is published in patents US 6689574 and WO02064632.

### **Summary of the invention**

- 25 The invention relates to novel disease associations of PPARD polypeptides and polynucleotides. The invention also relates to novel methods of screening for therapeutic agents for the treatment of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal. The invention also relates to  
30 pharmaceutical compositions for the treatment of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases,

metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising a PPARD polypeptide, a PPARD polynucleotide, or regulators of PPARD or modulators of PPARD activity. The invention further comprises methods of diagnosing cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal.

### **Brief Description of the Drawings**

Fig. 1 shows the nucleotide sequence of a PPARD receptor polynucleotide (SEQ ID NO: 1).

Fig. 2 shows the amino acid sequence of a PPARD receptor polypeptide (SEQ ID NO: 2).

Fig. 3 shows the nucleotide sequence of a primer useful for the invention (SEQ ID NO: 3).

Fig. 4 shows the nucleotide sequence of a primer useful for the invention (SEQ ID NO: 4).

Fig. 5 shows a nucleotide sequence useful as a probe to detect proteins of the invention (SEQ ID NO: 5).

### **Detailed description of the invention**

#### **Definition of terms**

An "oligonucleotide" is a stretch of nucleotide residues which has a sufficient number of bases to be used as an oligomer, amplimer or probe in a polymerase chain reaction (PCR). Oligonucleotides are prepared from genomic or cDNA sequence and are used to amplify, reveal, or confirm the presence of a similar DNA or RNA in a particular cell or tissue. Oligonucleotides or oligomers comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 35 nucleotides, preferably about 25 nucleotides.

"Probes" may be derived from naturally occurring or recombinant single- or double-stranded nucleic acids or may be chemically synthesized. They are useful in detecting the presence of identical or similar sequences. Such probes may be labeled with reporter molecules using nick translation, Klenow fill-in reaction, PCR or other methods well known in the art. Nucleic acid probes may be used in southern, northern or in situ hybridizations to determine whether DNA or RNA encoding a certain protein is present in a cell type, tissue, or organ.



A "fragment of a polynucleotide" is a nucleic acid that comprises all or any part of a given nucleotide molecule, the fragment having fewer nucleotides than about 6 kb, preferably fewer than about 1 kb.

5 "Reporter molecules" are radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents which associate with a particular nucleotide or amino acid sequence, thereby establishing the presence of a certain sequence, or allowing for the quantification of a certain sequence.

10 "Chimeric" molecules may be constructed by introducing all or part of the nucleotide sequence of this invention into a vector containing additional nucleic acid sequence which might be expected to change any one or several of the following PPARD characteristics: cellular location, distribution, ligand-binding affinities, interchain affinities, degradation/turnover rate, signaling, etc.

"Active", with respect to a PPARD polypeptide, refers to those forms, fragments, or domains of a PPARD polypeptide which retain the biological and/or antigenic activity of a PPARD polypeptide.

15 "Naturally occurring PPARD polypeptide" refers to a polypeptide produced by cells which have not been genetically engineered and specifically contemplates various polypeptides arising from post-translational modifications of the polypeptide including but not limited to acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation.

20 "Derivative" refers to polypeptides which have been chemically modified by techniques such as ubiquitination, labeling (see above), pegylation (derivatization with polyethylene glycol), and chemical insertion or substitution of amino acids such as ornithine which do not normally occur in human proteins.

"Conservative amino acid substitutions" result from replacing one amino acid with another having similar structural and/or chemical properties, such as the replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

25 "Insertions" or "deletions" are typically in the range of about 1 to 5 amino acids. The variation allowed may be experimentally determined by producing the peptide synthetically while systematically making insertions, deletions, or substitutions of nucleotides in the sequence using recombinant DNA techniques.

30 A "signal sequence" or "leader sequence" can be used, when desired, to direct the polypeptide through a membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous sources by recombinant DNA techniques.

An "oligopeptide" is a short stretch of amino acid residues and may be expressed from an oligonucleotide. Oligopeptides comprise a stretch of amino acid residues of at least 3, 5, 10 amino acids and at most 10, 15, 25 amino acids, typically of at least 9 to 13 amino acids, and of sufficient length to display biological and/or antigenic activity.

- 5 "Inhibitor" is any substance which retards or prevents a chemical or physiological reaction or response. Common inhibitors include but are not limited to antisense molecules, antibodies, and antagonists.

"Standard expression" is a quantitative or qualitative measurement for comparison. It is based on a statistically appropriate number of normal samples and is created to use as a basis of comparison  
10 when performing diagnostic assays, running clinical trials, or following patient treatment profiles.

"Animal" as used herein may be defined to include human, domestic (e.g., cats, dogs, etc.), agricultural (e.g., cows, horses, sheep, etc.) or test species (e.g., mouse, rat, rabbit, etc.).

A "PPARD polynucleotide", within the meaning of the invention, shall be understood as being a nucleic acid molecule selected from a group consisting of

- 15 (i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2,
- (ii) nucleic acid molecules comprising the sequence of SEQ ID NO: 1,
- (iii) nucleic acid molecules having the sequence of SEQ ID NO: 1,
- (iv) nucleic acid molecules the complementary strand of which hybridizes under stringent  
20 conditions to a nucleic acid molecule of (i), (ii), or (iii); and
- (v) nucleic acid molecules the sequence of which differs from the sequence of a nucleic acid molecule of (iii) due to the degeneracy of the genetic code;

wherein the polypeptide encoded by said nucleic acid molecule has PPARD activity.

A "PPARD polypeptide", within the meaning of the invention, shall be understood as being a  
25 polypeptide selected from a group consisting of

- (i) polypeptides having the sequence of SEQ ID NO: 2,
- (ii) polypeptides comprising the sequence of SEQ ID NO: 2,
- (iii) polypeptides encoded by PPARD polynucleotides; and

- (iv) polypeptides which show at least 99%, 98%, 95%, 90%, or 80% homology with a polypeptide of (i), (ii), or (iii);

wherein said polypeptide has PPARD activity.

5 The nucleotide sequences encoding a PPARD (or their complement) have numerous applications in techniques known to those skilled in the art of molecular biology. These techniques include use as hybridization probes, use in the construction of oligomers for PCR, use for chromosome and gene mapping, use in the recombinant production of PPARD, and use in generation of antisense DNA or RNA, their chemical analogs and the like. Uses of nucleotides encoding a PPARD disclosed herein are exemplary of known techniques and are not intended to limit their use in any  
10 technique known to a person of ordinary skill in the art. Furthermore, the nucleotide sequences disclosed herein may be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, e.g., the triplet genetic code, specific base pair interactions, etc.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic  
15 code, a multitude of PPARD - encoding nucleotide sequences may be produced. Some of these will only bear minimal homology to the nucleotide sequence of the known and naturally occurring PPARD. The invention has specifically contemplated each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as  
20 applied to the nucleotide sequence of naturally occurring PPARD, and all such variations are to be considered as being specifically disclosed.

Although the nucleotide sequences which encode a PPARD, its derivatives or its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring PPARD polynucleotide under stringent conditions, it may be advantageous to produce nucleotide  
25 sequences encoding PPARD polypeptides or its derivatives possessing a substantially different codon usage. Codons can be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding a PPARD polypeptide and/or its derivatives without altering the  
30 encoded amino acid sequence include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.



Nucleotide sequences encoding a PPARD polypeptide may be joined to a variety of other nucleotide sequences by means of well established recombinant DNA techniques. Useful nucleotide sequences for joining to PPARD polynucleotides include an assortment of cloning vectors such as plasmids, cosmids, lambda phage derivatives, phagemids, and the like. Vectors of interest include  
5 expression vectors, replication vectors, probe generation vectors, sequencing vectors, etc. In general, vectors of interest may contain an origin of replication functional in at least one organism, convenient restriction endonuclease sensitive sites, and selectable markers for one or more host cell systems.

Another aspect of the subject invention is to provide for PPARD-specific hybridization probes  
10 capable of hybridizing with naturally occurring nucleotide sequences encoding PPARD. Such probes may also be used for the detection of similar Nuclear Receptors encoding sequences and should preferably show at least 40% nucleotide identity to PPARD polynucleotides. The hybridization probes of the subject invention may be derived from the nucleotide sequence presented as SEQ ID NO: 1 or from genomic sequences including promoter, enhancers or introns  
15 of the native gene. Hybridization probes may be labelled by a variety of reporter molecules using techniques well known in the art.

It will be recognized that many deletional or mutational analogs of PPARD polynucleotides will be effective hybridization probes for PPARD polynucleotides. Accordingly, the invention relates to nucleic acid sequences that hybridize with such PPARD encoding nucleic acid sequences under  
20 stringent conditions.

"Stringent conditions" refers to conditions that allow for the hybridization of substantially related nucleic acid sequences. For instance, such conditions will generally allow hybridization of sequence with at least about 85% sequence identity, preferably with at least about 90% sequence identity, more preferably with at least about 95% sequence identity. Hybridization conditions and  
25 probes can be adjusted in well-characterized ways to achieve selective hybridization of human-derived probes. Stringent conditions, within the meaning of the invention are 65°C in a buffer containing 1 mM EDTA, 0.5 M NaHPO<sub>4</sub> (pH 7.2), 7 % (w/v) SDS.

Nucleic acid molecules that will hybridize to PPARD polynucleotides under stringent conditions can be identified functionally. Without limitation, examples of the uses for hybridization probes  
30 include: histochemical uses such as identifying tissues that express PPARD; measuring mRNA levels, for instance to identify a sample's tissue type or to identify cells that express abnormal levels of PPARD; and detecting polymorphisms of PPARD.

PCR provides additional uses for oligonucleotides based upon the nucleotide sequence which encodes PPARD. Such probes used in PCR may be of recombinant origin, chemically synthesized, or a mixture of both. Oligomers may comprise discrete nucleotide sequences employed under optimized conditions for identification of PPARD in specific tissues or diagnostic use. The same  
5 two oligomers, a nested set of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for identification of closely related DNAs or RNAs.

Rules for designing polymerase chain reaction (PCR) primers are now established, as reviewed by PCR Protocols. Degenerate primers, i.e., preparations of primers that are heterogeneous at given sequence locations, can be designed to amplify nucleic acid sequences that are highly homologous  
10 to, but not identical with PPARD. Strategies are now available that allow for only one of the primers to be required to specifically hybridize with a known sequence. For example, appropriate nucleic acid primers can be ligated to the nucleic acid sought to be amplified to provide the hybridization partner for one of the primers. In this way, only one of the primers need be based on the sequence of the nucleic acid sought to be amplified.

15 PCR methods for amplifying nucleic acid will utilize at least two primers. One of these primers will be capable of hybridizing to a first strand of the nucleic acid to be amplified and of priming enzyme-driven nucleic acid synthesis in a first direction. The other will be capable of hybridizing the reciprocal sequence of the first strand (if the sequence to be amplified is single stranded, this sequence will initially be hypothetical, but will be synthesized in the first amplification cycle) and  
20 of priming nucleic acid synthesis from that strand in the direction opposite the first direction and towards the site of hybridization for the first primer. Conditions for conducting such amplifications, particularly under preferred stringent hybridization conditions, are well known.

Other means of producing specific hybridization probes for PPARD include the cloning of nucleic acid sequences encoding PPARD or PPARD derivatives into vectors for the production of mRNA  
25 probes. Such vectors are known in the art, are commercially available and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerase as T7 or SP6 RNA polymerase and the appropriate reporter molecules.

It is possible to produce a DNA sequence, or portions thereof, entirely by synthetic chemistry. After synthesis, the nucleic acid sequence can be inserted into any of the many available DNA  
30 vectors and their respective host cells using techniques which are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into the nucleotide sequence. Alternately, a portion of sequence in which a mutation is desired can be synthesized and recombined with longer portion of an existing genomic or recombinant sequence.

PPARD polynucleotides may be used to produce a purified oligo-or polypeptide using well known methods of recombinant DNA technology. The oligopeptide may be expressed in a variety of host cells, either prokaryotic or eukaryotic. Host cells may be from the same species from which the nucleotide sequence was derived or from a different species. Advantages of producing an  
5 oligonucleotide by recombinant DNA technology include obtaining adequate amounts of the protein for purification and the availability of simplified purification procedures.

### **Quantitative determinations of nucleic acids**

An important step in the molecular genetic analysis of human disease is often the enumeration of the copy number of a nucleic acid or the relative expression of a gene in particular tissues.

10 Several different approaches are currently available to make quantitative determinations of nucleic acids. Chromosome-based techniques, such as comparative genomic hybridization (CGH) and fluorescent in situ hybridization (FISH) facilitate efforts to cytogenetically localize genomic regions that are altered in tumor cells. Regions of genomic alteration can be narrowed further using loss of heterozygosity analysis (LOH), in which disease DNA is analyzed and compared with  
15 normal DNA for the loss of a heterozygous polymorphic marker. The first experiments used restriction fragment length polymorphisms (RFLPs) [Johnson, (1989)], or hypervariable mini-satellite DNA [Barnes, 2000]. In recent years LOH has been performed primarily using PCR amplification of microsatellite markers and electrophoresis of the radio labelled [Jeffreys, (1985)] or fluorescently labelled PCR products [Weber, (1990)] and compared between paired normal and  
20 disease DNAs.

A number of other methods have also been developed to quantify nucleic acids [Gergen, (1992)]. More recently, PCR and RT-PCR methods have been developed which are capable of measuring the amount of a nucleic acid in a sample. One approach, for example, measures PCR product quantity in the log phase of the reaction before the formation of reaction products plateaus  
25 [Thomas, (1980)].

A gene sequence contained in all samples at relatively constant quantity is typically utilized for sample amplification efficiency normalization. This approach, however, suffers from several drawbacks. The method requires that each sample has equal input amounts of the nucleic acid and that the amplification efficiency between samples is identical until the time of analysis.  
30 Furthermore, it is difficult using the conventional methods of PCR quantitation such as gel electrophoresis or plate capture hybridization to determine that all samples are in fact analyzed during the log phase of the reaction as required by the method.

Another method called quantitative competitive (QC)-PCR, as the name implies, relies on the inclusion of an internal control competitor in each reaction [Piatak, (1993), BioTechniques]. The efficiency of each reaction is normalized to the internal competitor. A known amount of internal competitor is typically added to each sample. The unknown target PCR product is compared with the known competitor PCR product to obtain relative quantitation. A difficulty with this general approach lies in developing an internal control that amplifies with the same efficiency than the target molecule.

#### *5' Fluorogenic Nuclease Assays*

Fluorogenic nuclease assays are a real time quantitation method that uses a probe to monitor formation of amplification product. The basis for this method of monitoring the formation of amplification product is to measure continuously PCR product accumulation using a dual-labelled fluorogenic oligonucleotide probe, an approach frequently referred to in the literature simply as the "TaqMan method" [Piatak,(1993), Science; Heid, (1996); Gibson, (1996); Holland. (1991)].

The probe used in such assays is typically a short (about 20-25 bases) oligonucleotide that is labeled with two different fluorescent dyes. The 5' terminus of the probe is attached to a reporter dye and the 3' terminus is attached to a quenching dye, although the dyes could be attached at other locations on the probe as well. The probe is designed to have at least substantial sequence complementarity with the probe binding site. Upstream and downstream PCR primers which bind to flanking regions of the locus are added to the reaction mixture. When the probe is intact, energy transfer between the two fluorophors occurs and the quencher quenches emission from the reporter. During the extension phase of PCR, the probe is cleaved by the 5' nuclease activity of a nucleic acid polymerase such as Taq polymerase, thereby releasing the reporter from the oligonucleotide-quencher and resulting in an increase of reporter emission intensity which can be measured by an appropriate detector.

One detector which is specifically adapted for measuring fluorescence emissions such as those created during a fluorogenic assay is the ABI 7700 or 4700 HT manufactured by Applied Biosystems, Inc. in Foster City, Calif. The ABI 7700 uses fiber optics connected with each well in a 96-or 384 well PCR tube arrangement. The instrument includes a laser for exciting the labels and is capable of measuring the fluorescence spectra intensity from each tube with continuous monitoring during PCR amplification. Each tube is re-examined every 8.5 seconds.

Computer software provided with the instrument is capable of recording the fluorescence intensity of reporter and quencher over the course of the amplification. The recorded values will then be used to calculate the increase in normalized reporter emission intensity on a continuous basis. The



increase in emission intensity is plotted versus time, i.e., the number of amplification cycles, to produce a continuous measure of amplification. To quantify the locus in each amplification reaction, the amplification plot is examined at a point during the log phase of product accumulation. This is accomplished by assigning a fluorescence threshold intensity above background and  
5 determining the point at which each amplification plot crosses the threshold (defined as the threshold cycle number or Ct). Differences in threshold cycle number are used to quantify the relative amount of PCR target contained within each tube. Assuming that each reaction functions at 100% PCR efficiency, a difference of one Ct represents a two-fold difference in the amount of starting template. The fluorescence value can be used in conjunction with a standard curve to  
10 determine the amount of amplification product present.

#### *Non-Probe-Based Detection Methods*

A variety of options are available for measuring the amplification products as they are formed. One method utilizes labels, such as dyes, which only bind to double stranded DNA. In this type of approach, amplification product (which is double stranded) binds dye molecules in solution to  
15 form a complex. With the appropriate dyes, it is possible to distinguish between dye molecules free in solution and dye molecules bound to amplification product. For example, certain dyes fluoresce only when bound to amplification product. Examples of dyes which can be used in methods of this general type include, but are not limited to, Syber Green.TM. and Pico Green from Molecular Probes, Inc. of Eugene, Oreg., ethidium bromide, propidium iodide, chromomycin,  
20 acridine orange, Hoechst 33258, Toto-1, Yoyo-1, DAPI (4',6-diamidino-2-phenylindole hydrochloride).

Another real time detection technique measures alteration in energy fluorescence energy transfer between fluorophors conjugated with PCR primers [Livak, (1995)].

#### *Probe-Based Detection Methods*

25 These detection methods involve some alteration to the structure or conformation of a probe hybridized to the locus between the amplification primer pair. In some instances, the alteration is caused by the template-dependent extension catalyzed by a nucleic acid polymerase during the amplification process. The alteration generates a detectable signal which is an indirect measure of the amount of amplification product formed.

30 For example, some methods involve the degradation or digestion of the probe during the extension reaction. These methods are a consequence of the 5'-3' nuclease activity associated with some nucleic acid polymerases. Polymerases having this activity cleave mononucleotides or small

oligonucleotides from an oligonucleotide probe annealed to its complementary sequence located within the locus.

The 3' end of the upstream primer provides the initial binding site for the nucleic acid polymerase. As the polymerase catalyzes extension of the upstream primer and encounters the bound probe, the  
5 nucleic acid polymerase displaces a portion of the 5' end of the probe and through its nuclease activity cleaves mononucleotides or oligonucleotides from the probe.

The upstream primer and the probe can be designed such that they anneal to the complementary strand in close proximity to one another. In fact, the 3' end of the upstream primer and the 5' end of the probe may abut one another. In this situation, extension of the upstream primer is not  
10 necessary in order for the nucleic acid polymerase to begin cleaving the probe. In the case in which intervening nucleotides separate the upstream primer and the probe, extension of the primer is necessary before the nucleic acid polymerase encounters the 5' end of the probe. Once contact occurs and polymerization continues, the 5'-3' exonuclease activity of the nucleic acid polymerase begins cleaving mononucleotides or oligonucleotides from the 5' end of the probe. Digestion of  
15 the probe continues until the remaining portion of the probe dissociates from the complementary strand.

In solution, the two end sections can hybridize with each other to form a hairpin loop. In this conformation, the reporter and quencher dye are in sufficiently close proximity that fluorescence from the reporter dye is effectively quenched by the quencher dye. Hybridized probe, in contrast,  
20 results in a linearized conformation in which the extent of quenching is decreased. Thus, by monitoring emission changes for the two dyes, it is possible to indirectly monitor the formation of amplification product.

### *Probes*

The labeled probe is selected so that its sequence is substantially complementary to a segment of  
25 the test locus or a reference locus. As indicated above, the nucleic acid site to which the probe binds should be located between the primer binding sites for the upstream and downstream amplification primers.

### *Primers*

The primers used in the amplification are selected so as to be capable of hybridizing to sequences  
30 at flanking regions of the locus being amplified. The primers are chosen to have at least substantial complementarity with the different strands of the nucleic acid being amplified. When a

probe is utilized to detect the formation of amplification products, the primers are selected in such that they flank the probe, i.e. are located upstream and downstream of the probe.

5 The primer must have sufficient length so that it is capable of priming the synthesis of extension products in the presence of an agent for polymerization. The length and composition of the primer depends on many parameters, including, for example, the temperature at which the annealing reaction is conducted, proximity of the probe binding site to that of the primer, relative concentrations of the primer and probe and the particular nucleic acid composition of the probe. Typically the primer includes 15-30 nucleotides. However, the length of the primer may be more or less depending on the complexity of the primer binding site and the factors listed above.

#### 10 *Labels for Probes and Primers*

The labels used for labeling the probes or primers of the current invention and which can provide the signal corresponding to the quantity of amplification product can take a variety of forms. As indicated above with regard to the 5' fluorogenic nuclease method, a fluorescent signal is one signal which can be measured. However, measurements may also be made, for example, by  
15 monitoring radioactivity, colorimetry, absorption, magnetic parameters, or enzymatic activity. Thus, labels which can be employed include, but are not limited to, fluorophors, chromophores, radioactive isotopes, electron dense reagents, enzymes, and ligands having specific binding partners (e.g., biotin-avidin).

Monitoring changes in fluorescence is a particularly useful way to monitor the accumulation of  
20 amplification products. A number of labels useful for attachment to probes or primers are commercially available including fluorescein and various fluorescein derivatives such as FAM, HEX, TET and JOE (all which are available from Applied Biosystems, Foster City, Calif.); lucifer yellow, and coumarin derivatives.

Labels may be attached to the probe or primer using a variety of techniques and can be attached at  
25 the 5' end, and/or the 3' end and/or at an internal nucleotide. The label can also be attached to spacer arms of various sizes which are attached to the probe or primer. These spacer arms are useful for obtaining a desired distance between multiple labels attached to the probe or primer.

In some instances, a single label may be utilized; whereas, in other instances, such as with the 5' fluorogenic nuclease assays for example, two or more labels are attached to the probe. In cases  
30 wherein the probe includes multiple labels, it is generally advisable to maintain spacing between the labels which is sufficient to permit separation of the labels during digestion of the probe through the 5'-3' nuclease activity of the nucleic acid polymerase.

**Patients Exhibiting Symptoms of Disease**

A number of diseases are associated with changes in the copy number of a certain gene. For patients having symptoms of a disease, the real-time PCR method can be used to determine if the patient has copy number alterations which are known to be linked with diseases that are associated  
5 with the symptoms the patient has.

**PPARD expression***PPARD fusion proteins*

Fusion proteins are useful for generating antibodies against PPARD polypeptides and for use in various assay systems. For example, fusion proteins can be used to identify proteins which  
10 interact with portions of PPARD polypeptides. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.

A PPARD fusion protein comprises two polypeptide segments fused together by means of a  
15 peptide bond. The first polypeptide segment can comprise at least 54, 75, 100, 125, 139, 150, 175, 200, 225, 250, or 275 contiguous amino acids of SEQ ID NO: 2 or of a biologically active variant, such as those described above. The first polypeptide segment also can comprise full-length PPARD.

The second polypeptide segment can be a full-length protein or a protein fragment. Proteins  
20 commonly used in fusion protein construction include, but are not limited to  $\beta$ -galactosidase,  $\beta$ -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT). Additionally, epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin  
25 (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, herpes simplex virus (HSV) BP16 protein fusions and G-protein fusions (for example G(alpha)16, Gs, Gi). A fusion protein also can be engineered to contain a cleavage site located adjacent to the PPARD.



*Preparation of Polynucleotides*

A naturally occurring PPARD polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids. Polynucleotides can be made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification  
5 technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated PPARD polynucleotides. For example, restriction enzymes and probes can be used to isolate polynucleotide fragments which comprise PPARD nucleotide sequences. Isolated polynucleotides are in preparations which are  
10 free or at least 70, 80, or 90% free of other molecules.

PPARD cDNA molecules can be made with standard molecular biology techniques, using PPARD mRNA as a template. PPARD cDNA molecules can thereafter be replicated using molecular biology techniques known in the art. An amplification technique, such as PCR, can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or  
15 cDNA as a template.

---

Alternatively, synthetic chemistry techniques can be used to synthesize PPARD polynucleotides. The degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which will encode PPARD having, for example, an amino acid sequence shown in SEQ ID NO: 2 or a biologically active variant thereof.

*20 Extending Polynucleotides*

Various PCR-based methods can be used to extend nucleic acid sequences encoding human PPARD, for example to detect upstream sequences of PPARD gene such as promoters and regulatory elements. For example, restriction-site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus. Genomic DNA is first amplified in the presence of a primer  
25 to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a  
30 known region. Primers can be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Plymouth, Minn.), to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at

temperatures about 68-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

5 Another method which can be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA. In this method, multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

10 When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Randomly-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' non-transcribed regulatory regions.

15 Commercially available capillary electrophoresis systems can be used to analyze the size or confirm the nucleotide sequence of PCR or sequencing products. For example, capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity can be converted to electrical signal  
20 using appropriate equipment and software (e.g., GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the entire process from loading of samples to computer analysis and electronic data display can be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

## 25 *Obtaining Polypeptides*

PPARD can be obtained, for example, by purification from human cells, by expression of PPARD polynucleotides, or by direct chemical synthesis.

### *Protein Purification*

30 PPARD can be purified from any human cell which expresses the receptor, including those which have been transfected with expression constructs which express PPARD. A purified PPARD is separated from other compounds which normally associate with PPARD in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art. Such methods include, but

are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis.

#### *Expression of PPARD Polynucleotides*

To express PPARD, PPARD polynucleotides can be inserted into an expression vector which  
5 contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art can be used to construct expression vectors containing sequences encoding PPARD and appropriate transcriptional and translational control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination.

10 A variety of expression vector/host systems can be utilized to contain and express sequences encoding PPARD. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect cell systems infected with virus expression vectors (*e.g.*, baculovirus), plant cell systems transformed with virus expression vectors (*e.g.*,  
15 cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (*e.g.*, Ti or pBR322 plasmids), or animal cell systems.

The control elements or regulatory sequences are those non-translated regions of the vector -- enhancers, promoters, 5' and 3' untranslated regions -- which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity.  
20 Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORT1 plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin promoter can be used in insect cells.  
25 Promoters or enhancers derived from the genomes of plant cells (*e.g.*, heat shock, RUBISCO, and storage protein genes) or from plant viruses (*e.g.*, viral promoters or leader sequences) can be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding PPARD, vectors based on SV40 or EBV can be used  
30 with an appropriate selectable marker.

### *Bacterial and Yeast Expression Systems*

In bacterial systems, a number of expression vectors can be selected. For example, when a large quantity of PPARD is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene). In a BLUESCRIPT vector, a sequence encoding PPARD can be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of  $\beta$ -galactosidase so that a hybrid protein is produced. pIN vectors or pGEX vectors (Promega, Madison, Wis.) also can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

### 15 *Plant and Insect Expression Systems*

If plant expression vectors are used, the expression of sequences encoding PPARD can be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used. These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection.

An insect system also can be used to express PPARD. For example, in one such system *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. Sequences encoding PPARD can be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of PPARD will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which PPARD can be expressed.

### 30 *Mammalian Expression Systems*

A number of viral-based expression systems can be used to express PPARD in mammalian host cells. For example, if an adenovirus is used as an expression vector, sequences encoding PPARD



can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome can be used to obtain a viable virus which is capable of expressing PPARD in infected host cells [Engelhard, 1994]]. If desired, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) also can be used to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6M to 10M are constructed and delivered to cells via conventional delivery methods (*e.g.*, liposomes, polycationic amino polymers, or vesicles). Specific initiation signals also can be used to achieve more efficient translation of sequences encoding PPARD. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding PPARD, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic.

### *Host Cells*

A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed PPARD in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (*e.g.*, CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209) and can be chosen to ensure the correct modification and processing of the foreign protein.

Stable expression is preferred for long-term, high-yield production of recombinant proteins. For example, cell lines which stably express PPARD can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 1-2 days in an enriched medium before they are switched to a selective medium. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced

PPARD sequences. Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. Any number of selection systems can be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase [Logan, (1984)] and adenine phosphoribosyltransferase [Wigler, (1977)] genes which can be employed in *tk* or *aprt* cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate [Lowy, (1980)], *npt* confers resistance to the aminoglycosides, neomycin and G-418 [Wigler, (1980)], and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively [Colbere-Garapin, 1981]. Additional selectable genes have been described. For example, *trpB* allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine. Visible markers such as anthocyanins,  $\beta$ -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific vector system

#### 15 *Detecting Polypeptide Expression*

Although the presence of marker gene expression suggests that a PPARD polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding PPARD is inserted within a marker gene sequence, transformed cells containing sequences which encode PPARD can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding PPARD under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of PPARD polynucleotide.

Alternatively, host cells which contain a PPARD polynucleotide and which express PPARD can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein. For example, the presence of a polynucleotide sequence encoding PPARD can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding PPARD. Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding PPARD to detect transformants which contain a PPARD polynucleotide.

A variety of protocols for detecting and measuring the expression of PPARD, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence

activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on PPARD can be used, or a competitive binding assay can be employed.

5 A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding PPARD include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, sequences encoding PPARD can be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and can be used to  
10 synthesize RNA probes *in vitro* by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radio-nuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as  
15 substrates, cofactors, inhibitors, magnetic particles, and the like.

#### *Expression and Purification of Polypeptides*

Host cells transformed with PPARD polynucleotides can be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The polypeptide produced by a transformed cell can be secreted or contained intracellularly depending on the sequence and/or the  
20 vector used. As will be understood by those of skill in the art, expression vectors containing PPARD polynucleotides can be designed to contain signal sequences which direct secretion of soluble PPARD through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound PPARD.

As discussed above, other constructions can be used to join a sequence encoding PPARD to a  
25 nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.).  
30 Inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and PPARD also can be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing PPARD and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilized metal ion affinity



chromatography) Maddox, (1983)], while the enterokinase cleavage site provides a means for purifying PPARD from the fusion protein [Porath, (1992)].

### *Chemical Synthesis*

Sequences encoding PPARD can be synthesized, in whole or in part, using chemical methods well known in the art. Alternatively, PPARD itself can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques. Protein synthesis can either be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Optionally, fragments of PPARD can be separately synthesized and combined using chemical methods to produce a full-length molecule.

The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography. The composition of a synthetic PPARD can be confirmed by amino acid analysis or sequencing. Additionally, any portion of the amino acid sequence of PPARD can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.

### *Production of Altered Polypeptides*

As will be understood by those of skill in the art, it may be advantageous to produce PPARD polynucleotides possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences referred to herein can be engineered using methods generally known in the art to alter PPARD polynucleotides for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences. For example, site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

### *Antibodies*

Any type of antibody known in the art can be generated to bind specifically to an epitope of PPARD.



“Antibody” as used herein includes intact immunoglobulin molecules, as well as fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv, which are capable of binding an epitope of PPARD. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous amino acids may require more, *e.g.*, at least 15,  
5 25, or 50 amino acid. An antibody which specifically binds to an epitope of PPARD can be used therapeutically, as well as in immunochemical assays, such as Western blots, ELISAs, radio-immunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art. Various immunoassays can be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays are  
10 well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody which specifically binds to the PPARD immunogen.

Typically, an antibody which specifically binds to PPARD provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an  
15 immunochemical assay. Preferably, antibodies which specifically bind to PPARD do not detect other proteins in immunochemical assays and can immunoprecipitate PPARD from solution.

PPARD can be used to immunize a mammal, such as a mouse, rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies. If desired, PPARD can be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin. Depending  
20 on the host species, various adjuvants can be used to increase the immunological response. Such adjuvants include, but are not limited to, Freund's adjuvant, mineral gels (*e.g.*, aluminum hydroxide), and surface active substances (*e.g.*, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol). Among adjuvants used in humans, BCG (*bacilli Calmette-Guerin*) and *Corynebacterium parvum* are especially useful.

25 Monoclonal antibodies which specifically bind to PPARD can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These techniques include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique [Roberge, (1995)].

In addition, techniques developed for the production of “chimeric antibodies”, the splicing of  
30 mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. Monoclonal and other antibodies also can be “humanized” to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues. Sequence

differences between rodent antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grating of entire complementarity determining regions. Antibodies which specifically bind to PPARD can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. 5,565,332.

Alternatively, techniques described for the production of single chain antibodies can be adapted using methods known in the art to produce single chain antibodies which specifically bind to PPARD. Antibodies with related specificity, but of distinct idiotypic composition, can be generated by chain shuffling from random combinatorial immunoglobulin libraries. Single-chain antibodies also can be constructed using a DNA amplification method, such as PCR, using hybridoma cDNA as a template. Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain antibodies is taught. A nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using standard recombinant DNA methods, and introduced into a cell to express the coding sequence, as described below. Alternatively, single-chain antibodies can be produced directly using, for example, filamentous phage technology.

Antibodies which specifically bind to PPARD also can be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents. Other types of antibodies can be constructed and used therapeutically in methods of the invention. For example, chimeric antibodies can be constructed as disclosed in WO 93/03151. Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, also can be prepared.

Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which PPARD is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.

#### *Antisense Oligonucleotides*

Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 11 nucleotides in length, but can be

at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of PPARD gene products in the cell.

Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, or a combination of both. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such as alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters.

Modifications of PPARD gene expression can be obtained by designing antisense oligonucleotides which will form duplexes to the control, 5', or regulatory regions of the PPARD gene. Oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons. Therapeutic advances using triplex-DNA have been described in the literature [Nicholls, (1993)]. An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Precise complementarity is not required for successful complex formation between an antisense oligonucleotide and the complementary sequence of a PPARD polynucleotide. Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a PPARD polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent PPARD nucleotides, can provide sufficient targeting specificity for PPARD mRNA. Preferably, each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length. Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in length. One skilled in the art can easily use the calculated melting point of an antisense-sense pair to determine the degree of mismatching which will be tolerated between a particular antisense oligonucleotide and a particular PPARD polynucleotide sequence. Antisense oligonucleotides can be modified without affecting their ability to hybridize to a PPARD polynucleotide. These modifications can be internal or at one or both ends of the antisense molecule. For example, internucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose. Modified bases and/or sugars, such as arabinose instead of ribose, or a 3', 5'-substituted oligonucleotide in which the 3' hydroxyl



group or the 5' phosphate group are substituted, also can be employed in a modified antisense oligonucleotide. These modified oligonucleotides can be prepared by methods well known in the art.

### *Ribozymes*

5 Ribozymes are RNA molecules with catalytic activity [Uhlmann, (1987)]. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endo-  
10 nucleolytic cleavage of specific nucleotide sequences. The coding sequence of a PPARD polynucleotide can be used to generate ribozymes which will specifically bind to mRNA transcribed from a PPARD polynucleotide. Methods of designing and constructing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art. For example, the cleavage activity of ribozymes can be targeted to  
15 specific RNAs by engineering a discrete "hybridization" region into the ribozyme. The hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target RNA.

Specific ribozyme cleavage sites within a PPARD RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU,  
20 and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate PPARD RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays. The nucleotide sequences  
25 shown in SEQ ID NO: 1 and its complement provide sources of suitable hybridization region sequences. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target. The hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.

30 Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease PPARD expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element

or integrated into the genome of the cells, as is known in the art. A ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells (U.S. 5,641,673). Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.

## Screening / Screening Assays

### *Regulators*

Regulators as used herein, refer to compounds that affect the activity of a PPARD in vivo and/or in vivo. Regulators can be agonists and antagonists of a PPARD polypeptide and can be compounds that exert their effect on the PPARD activity via the expression, via post-translational modifications or by other means. Agonists of PPARD are molecules which, when bound to PPARD, increase or prolong the activity of PPARD. Agonists of PPARD include proteins, nucleic acids, carbohydrates, small molecules, or any other molecule which activate PPARD. Antagonists of PPARD are molecules which, when bound to PPARD, decrease the amount or the duration of the activity of PPARD. Antagonists include proteins, nucleic acids, carbohydrates, antibodies, small molecules, or any other molecule which decrease the activity of PPARD.

The term "modulate", as it appears herein, refers to a change in the activity of PPARD polypeptide. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of PPARD.

As used herein, the terms "specific binding" or "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein recognized by the binding molecule (i.e., the antigenic determinant or epitope). For example, if an antibody is specific for epitope "A" the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The invention provides methods (also referred to herein as "screening assays") for identifying compounds which can be used for the treatment of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases. The methods entail the identification of candidate or test compounds or

agents (e.g., peptides, peptidomimetics, small molecules or other molecules) which bind to PPARD and/or have a stimulatory or inhibitory effect on the biological activity of PPARD or its expression and then determining which of these compounds have an effect on symptoms or diseases regarding the cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in an *in vivo* assay.

Candidate or test compounds or agents which bind to PPARD and/or have a stimulatory or inhibitory effect on the activity or the expression of PPARD are identified either in assays that employ cells which express PPARD on the cell surface (cell-based assays) or in assays with isolated PPARD (cell-free assays). The various assays can employ a variety of variants of PPARD (e.g., full-length PPARD, a biologically active fragment of PPARD, or a fusion protein which includes all or a portion of PPARD). Moreover, PPARD can be derived from any suitable mammalian species (e.g., human PPARD, rat PPARD or murine PPARD). The assay can be a binding assay entailing direct or indirect measurement of the binding of a test compound or a known PPARD ligand to PPARD. The assay can also be an activity assay entailing direct or indirect measurement of the activity of PPARD. The assay can also be an expression assay entailing direct or indirect measurement of the expression of PPARD mRNA or PPARD protein. The various screening assays are combined with an *in vivo* assay entailing measuring the effect of the test compound on the symptoms of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases.

Determining the ability of the test compound to modulate the activity of PPARD can be accomplished, for example, by determining the ability of PPARD to bind to or interact with a target molecule. The target molecule can be a molecule with which PPARD binds or interacts with in nature, for example, a molecule from the extracellular milieu able to traverse the cytoplasmic membrane or a cytoplasmic molecule. The target molecule can be a component of a signal transduction pathway which facilitates transduction of an extracellular signal (e.g., a signal generated by another cell) through the cell membrane and into the cell. The target PPARD molecule can be, for example, a second intracellular protein which has catalytic activity, a protein which facilitates the association of downstream signaling molecules with PPARD or the target DNA of the nuclear receptor.

**Nuclear receptor assays**

In general two modes exist to determine ligand dependent NR activity in cell based assays. Cells that endogenously express a certain NR can be transfected with a reporter construct expressing a reporter gene (e.g. firefly luciferase) under control of a responsive promoter (Gutendorf et al., 2001). Alternatively cells lacking an endogenous NR are co-transfected with a reporter construct and a NR expressing vector (Berger et al., 1992).

In a second approach a fusion protein of the NRs LBD and a non-mammalian DBD, that targets a corresponding promoter with a downstream reporter gene, are used. DBD from the bacterial LexA repressor or the yeast Gal4 transcription activator are described (Lee et al., 1998; Charles et al., 2000). The corresponding reporter constructs are formed by a minimal promoter containing binding sites for LexA or Gal4 respectively.

Both systems are induced by addition of the receptor activating ligands and the expression level of the reporter reflects transcription activation by the NR.

Binding of ligands to NRs can also be detected in competition-binding assays with purified NRs or NR LBDs. A specific radiolabeled ligand binds to NRs in the presence of unlabeled test compounds. The amount of receptor-bound radioactivity gives information about the affinity of the test compounds. In the scintillation proximity assay (SPA) biotinylated NR LBDs are linked to streptavidine coated beads impregnated with scintillant (Nichols et al., 1998). Radioactive counts are observed only when the receptor-ligand complex is captured on the surface of the bead, eliminating the need to separate bound from free ligand. Therefore SPA is fully automatable and compatible to high throughput.

The homogenous fluorescence polarization-based ligand-binding assay utilizes His- and GST-tagged LBDs of steroid NR and a selective high affinity fluorescent-labeled ligand (Rosen et al., 2003). The binding affinity of a test compound is determined by displacement of the fluorescent steroid, accompanied by a change in the polarization value.

The competition assays are sensitive tools to identify NR ligands but cannot distinguish between agonists or antagonists, because only the affinity not the potential to induce conformational changes is measured.

The present invention also includes cell-free assays. Such assays involve contacting a form of PPARD (e.g., full-length PPARD, a biologically active fragment of PPARD, or a fusion protein comprising all or a portion of PPARD) with a test compound and determining the ability of the test compound to bind to PPARD. Binding of the test compound to PPARD can be determined either



directly or indirectly as described above. In one embodiment, the assay includes contacting PPARD with a known compound which binds PPARD to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with PPARD, wherein determining the ability of the test compound to interact with PPARD  
5 comprises determining the ability of the test compound to preferentially bind to PPARD as compared to the known compound.

The cell-free assays of the present invention are amenable to use of either a membrane-bound form of PPARD or a soluble fragment thereof. In the case of cell-free assays comprising the membrane-bound form of the polypeptide, it may be desirable to utilize a solubilizing agent such that the  
10 membrane-bound form of the polypeptide is maintained in solution. Examples of such solubilizing agents include but are not limited to non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton X-100, Triton X-114, Thesit, Isotridecypoly(ethylene glycol ether)n, 3-[(3-cholamidopropyl)-dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-  
15 hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

In various embodiments of the above assay methods of the present invention, it may be desirable to immobilize PPARD (or a PPARD target molecule) to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the  
20 assay. Binding of a test compound to PPARD, or interaction of PPARD with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase  
25 (GST) fusion proteins or glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical; St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or PPARD, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the  
30 beads or microtitre plate wells are washed to remove any unbound components and complex formation is measured either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of binding or activity of PPARD can be determined using standard techniques.



Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either PPARD or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated polypeptide of the invention or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, Ill.), and immobilized in the wells of streptavidin-coated plates (Pierce Chemical). Alternatively, antibodies reactive with PPARD or target molecules but which do not interfere with binding of the polypeptide of the invention to its target molecule can be derivatized to the wells of the plate, and unbound target or polypeptide of the invention trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with PPARD or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with PPARD or target molecule.

The screening assay can also involve monitoring the expression of PPARD. For example, regulators of expression of PPARD can be identified in a method in which a cell is contacted with a candidate compound and the expression of PPARD protein or mRNA in the cell is determined.

The level of expression of PPARD protein or mRNA the presence of the candidate compound is compared to the level of expression of PPARD protein or mRNA in the absence of the candidate compound. The candidate compound can then be identified as a regulator of expression of PPARD based on this comparison. For example, when expression of PPARD protein or mRNA protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of PPARD protein or mRNA expression. Alternatively, when expression of PPARD protein or mRNA is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of PPARD protein or mRNA expression. The level of PPARD protein or mRNA expression in the cells can be determined by methods described below.

#### *Binding Assays*

For binding assays, the test compound is preferably a small molecule which binds to and occupies the active site of PPARD polypeptide, thereby making the ligand binding site inaccessible to substrate such that normal biological activity is prevented. Examples of such small molecules include, but are not limited to, small peptides or peptide-like molecules. Potential ligands which bind to a polypeptide of the invention include, but are not limited to, the natural ligands of known PPARD Nuclear Receptors and analogues or derivatives thereof.

In binding assays, either the test compound or the PPARD polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horse-radish peroxidase, alkaline phosphatase, or luciferase. Detection of a test compound which is bound to PPARD polypeptide can then be accomplished, for example, by direct counting of radioemmission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product. Alternatively, binding of a test compound to a PPARD polypeptide can be determined without labeling either of the interactants. For example, a microphysiometer can be used to detect binding of a test compound with a PPARD polypeptide. A microphysiometer (*e.g.*, Cytosensor™) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a test compound and PPARD [Haseloff, (1988)].

Determining the ability of a test compound to bind to PPARD also can be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) [McConnell, (1992); Sjolander, (1991)]. BIA is a technology for studying biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIAcore™). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In yet another aspect of the invention, a PPARD-like polypeptide can be used as a "bait protein" in a two-hybrid assay or three-hybrid assay [Szabo, (1995); U.S. 5,283,317], to identify other proteins which bind to or interact with PPARD and modulate its activity.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. For example, in one construct, polynucleotide encoding PPARD can be fused to a polynucleotide encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct a DNA sequence that encodes an unidentified protein ("prey" or "sample") can be fused to a polynucleotide that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact *in vivo* to form an protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ), which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein which interacts with PPARD.

It may be desirable to immobilize either the PPARD (or polynucleotide) or the test compound to facilitate separation of the bound form from unbound forms of one or both of the interactants, as well as to accommodate automation of the assay. Thus, either the PPARD-like polypeptide (or polynucleotide) or the test compound can be bound to a solid support. Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art can be used to attach PPARD-like polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide) or test compound and the solid support. Test compounds are preferably bound to the solid support in an array, so that the location of individual test compounds can be tracked. Binding of a test compound to PPARD (or a polynucleotide encoding for PPARD) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.

In one embodiment, PPARD is a fusion protein comprising a domain that allows binding of PPARD to a solid support. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and the non-adsorbed PPARD; the mixture is then incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components. Binding of the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined.

Other techniques for immobilizing proteins or polynucleotides on a solid support also can be used in the screening assays of the invention. For example, either PPARD (or a polynucleotide encoding PPARD) or a test compound can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated PPARD (or a polynucleotide encoding biotinylated PPARD) or test compounds can be prepared from biotin-NHS (N-hydroxysuccinimide) using techniques well known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized in the wells of streptavidin-coated plates (Pierce Chemical). Alternatively, antibodies which specifically bind to PPARD, polynucleotide, or a test compound, but which do not interfere with a desired binding site, such as the active site of PPARD, can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.



Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies which specifically bind to PPARD polypeptide or test compound, enzyme-linked assays which rely on detecting an activity of PPARD polypeptide, and SDS gel electrophoresis under non-reducing conditions.

- 5 Screening for test compounds which bind to a PPARD polypeptide or polynucleotide also can be carried out in an intact cell. Any cell which comprises a PPARD polypeptide or polynucleotide can be used in a cell-based assay system. A PPARD polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Binding of the test compound to PPARD or a polynucleotide encoding PPARD is determined as described above.

#### 10 *Test Compounds*

- Suitable test compounds for use in the screening assays of the invention can be obtained from any suitable source, e.g., conventional compound libraries. The test compounds can also be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; 15 synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds [Lam, (1997)]. Examples of methods for the synthesis of molecular libraries can be found in the art. Libraries of compounds 20 may be presented in solution or on beads, bacteria, spores, plasmids or phage.

#### *Modeling of Regulators*

- Computer modeling and searching technologies permit identification of compounds, or the improvement of already identified compounds, that can modulate PPARD expression or activity. Having identified such a compound or composition, the active sites or regions are identified. Such 25 active sites might typically be ligand binding sites, such as the interaction domain of the ligand with PPARD. The active site can be identified using methods known in the art including, for example, from the amino acid sequences of peptides, from the nucleotide sequences of nucleic acids, or from study of complexes of the relevant compound or composition with its natural ligand. In the latter case, chemical or X-ray crystallographic methods can be used to find the active site by 30 finding where on the factor the complexed ligand is found.

Next, the three dimensional geometric structure of the active site is determined. This can be done by known methods, including X-ray crystallography, which can determine a complete molecular



structure. On the other hand, solid or liquid phase NMR can be used to determine certain intramolecular distances. Any other experimental method of structure determination can be used to obtain partial or complete geometric structures. The geometric structures may be measured with a complexed ligand, natural or artificial, which may increase the accuracy of the active site structure determined.

If an incomplete or insufficiently accurate structure is determined, the methods of computer based numerical modeling can be used to complete the structure or improve its accuracy. Any recognized modeling method may be used, including parameterized models specific to particular biopolymers such as proteins or nucleic acids, molecular dynamics models based on computing molecular motions, statistical mechanics models based on thermal ensembles, or combined models. For most types of models, standard molecular force fields, representing the forces between constituent atoms and groups, are necessary, and can be selected from force fields known in physical chemistry. The incomplete or less accurate experimental structures can serve as constraints on the complete and more accurate structures computed by these modeling methods.

Finally, having determined the structure of the active site, either experimentally, by modeling, or by a combination, candidate modulating compounds can be identified by searching databases containing compounds along with information on their molecular structure. Such a search seeks compounds having structures that match the determined active site structure and that interact with the groups defining the active site. Such a search can be manual, but is preferably computer assisted. These compounds found from this search are potential PPARD modulating compounds.

Alternatively, these methods can be used to identify improved modulating compounds from an already known modulating compound or ligand. The composition of the known compound can be modified and the structural effects of modification can be determined using the experimental and computer modeling methods described above applied to the new composition. The altered structure is then compared to the active site structure of the compound to determine if an improved fit or interaction results. In this manner systematic variations in composition, such as by varying side groups, can be quickly evaluated to obtain modified modulating compounds or ligands of improved specificity or activity.

#### **Therapeutic Indications and Methods**

It was found by the present applicant that PPARD is expressed in various human tissues.

*Neurology*

CNS disorders include disorders of the central nervous system as well as disorders of the peripheral nervous system.

CNS disorders include, but are not limited to brain injuries, cerebrovascular diseases and their consequences, Parkinson's disease, corticobasal degeneration, motor neuron disease, dementia, including ALS, multiple sclerosis, traumatic brain injury, stroke, post-stroke, post-traumatic brain injury, and small-vessel cerebrovascular disease. Dementias, such as Alzheimer's disease, vascular dementia, dementia with Lewy bodies, frontotemporal dementia and Parkinsonism linked to chromosome 17, frontotemporal dementias, including Pick's disease, progressive nuclear palsy, corticobasal degeneration, Huntington's disease, thalamic degeneration, Creutzfeld-Jakob dementia, HIV dementia, schizophrenia with dementia, and Korsakoff's psychosis, within the meaning of the definition are also considered to be CNS disorders.

Similarly, cognitive-related disorders, such as mild cognitive impairment, age-associated memory impairment, age-related cognitive decline, vascular cognitive impairment, attention deficit disorders, attention deficit hyperactivity disorders, and memory disturbances in children with learning disabilities are also considered to be CNS disorders.

Pain, within the meaning of this definition, is also considered to be a CNS disorder. Pain can be associated with CNS disorders, such as multiple sclerosis, spinal cord injury, sciatica, failed back surgery syndrome, traumatic brain injury, epilepsy, Parkinson's disease, post-stroke, and vascular lesions in the brain and spinal cord (e.g., infarct, hemorrhage, vascular malformation). Non-central neuropathic pain includes that associated with post mastectomy pain, phantom feeling, reflex sympathetic dystrophy (RSD), trigeminal neuralgia, radioculopathy, post-surgical pain, HIV/AIDS related pain, cancer pain, metabolic neuropathies (e.g., diabetic neuropathy, vasculitic neuropathy secondary to connective tissue disease), paraneoplastic polyneuropathy associated, for example, with carcinoma of lung, or leukemia, or lymphoma, or carcinoma of prostate, colon or stomach, trigeminal neuralgia, cranial neuralgias, and post-herpetic neuralgia. Pain associated with peripheral nerve damage, central pain (i.e. due to cerebral ischemia) and various chronic pain i.e., lumbago, back pain (low back pain), inflammatory and/or rheumatic pain. Headache pain (for example, migraine with aura, migraine without aura, and other migraine disorders), episodic and chronic tension-type headache, tension-type like headache, cluster headache, and chronic paroxysmal hemicrania are also CNS disorders.

Visceral pain such as pancreatitis, intestinal cystitis, dysmenorrhea, irritable Bowel syndrome, Crohn's disease, biliary colic, ureteral colic, myocardial infarction and pain syndromes of the

pelvic cavity, e.g., vulvodynia, orchialgia, urethral syndrome and protatodynia are also CNS disorders.

Also considered to be a disorder of the nervous system are acute pain, for example postoperative pain, and pain after trauma.

- 5 The human PPAR-delta is highly expressed in the following brain tissues: brain, cerebral cortex, frontal lobe, occipital lobe, parietal lobe, temporal lobe, caudatum, corpus callosum, hippocampus, thalamus, hypothalamus, spinal cord, glial tumor H4 cells. The expression in brain tissues demonstrates that the human PPAR-delta or mRNA can be utilized to diagnose nervous system diseases. Additionally the activity of the human PPAR-delta can be modulated to treat nervous  
10 system diseases.

#### *Cardiovascular Disorders*

- Heart failure is defined as a pathophysiological state in which an abnormality of cardiac function is responsible for the failure of the heart to pump blood at a rate commensurate with the requirement of the metabolizing tissue. It includes all forms of pumping failures such as high-output and low-  
15 output, acute and chronic, right-sided or left-sided, systolic or diastolic, independent of the underlying cause.

- Myocardial infarction (MI) is generally caused by an abrupt decrease in coronary blood flow that follows a thrombotic occlusion of a coronary artery previously narrowed by arteriosclerosis. MI prophylaxis (primary and secondary prevention) is included as well as the acute treatment of MI  
20 and the prevention of complications.

Ischemic diseases are conditions in which the coronary flow is restricted resulting in a perfusion which is inadequate to meet the myocardial requirement for oxygen. This group of diseases includes stable angina, unstable angina and asymptomatic ischemia.

- 25 Arrhythmias include all forms of atrial and ventricular tachyarrhythmias, atrial tachycardia, atrial flutter, atrial fibrillation, atrio-ventricular reentrant tachycardia, preexcitation syndrome, ventricular tachycardia, ventricular flutter, ventricular fibrillation, as well as bradycardic forms of arrhythmias.

- Hypertensive vascular diseases include primary as well as all kinds of secondary arterial  
30 hypertension, renal, endocrine, neurogenic, others. The genes may be used as drug targets for the

treatment of hypertension as well as for the prevention of all complications arising from cardiovascular diseases.

Peripheral vascular diseases are defined as vascular diseases in which arterial and/or venous flow is reduced resulting in an imbalance between blood supply and tissue oxygen demand. It includes  
5 chronic peripheral arterial occlusive disease (PAOD), acute arterial thrombosis and embolism, inflammatory vascular disorders, Raynaud's phenomenon and venous disorders.

Atherosclerosis is a cardiovascular disease in which the vessel wall is remodeled, compromising the lumen of the vessel. The atherosclerotic remodeling process involves accumulation of cells, both smooth muscle cells and monocyte/macrophage inflammatory cells, in the intima of the vessel  
10 wall. These cells take up lipid, likely from the circulation, to form a mature atherosclerotic lesion. Although the formation of these lesions is a chronic process, occurring over decades of an adult human life, the majority of the morbidity associated with atherosclerosis occurs when a lesion ruptures, releasing thrombogenic debris that rapidly occludes the artery. When such an acute event occurs in the coronary artery, myocardial infarction can ensue, and in the worst case, can result in  
15 death.

The formation of the atherosclerotic lesion can be considered to occur in five overlapping stages such as migration, lipid accumulation, recruitment of inflammatory cells, proliferation of vascular smooth muscle cells, and extracellular matrix deposition. Each of these processes can be shown to occur in man and in animal models of atherosclerosis, but the relative contribution of each to the  
20 pathology and clinical significance of the lesion is unclear.

Thus, a need exists for therapeutic methods and agents to treat cardiovascular pathologies, such as atherosclerosis and other conditions related to coronary artery disease.

Cardiovascular diseases include but are not limited to disorders of the heart and the vascular system like congestive heart failure, myocardial infarction, ischemic diseases of the heart, all  
25 kinds of atrial and ventricular arrhythmias, hypertensive vascular diseases, peripheral vascular diseases, and atherosclerosis.

Too high or too low levels of fats in the bloodstream, especially cholesterol, can cause long-term problems. The risk to develop atherosclerosis and coronary artery or carotid artery disease (and thus the risk of having a heart attack or stroke) increases with the total cholesterol level increasing.  
30 Nevertheless, extremely low cholesterol levels may not be healthy. Examples of disorders of lipid metabolism are hyperlipidemia (abnormally high levels of fats (cholesterol, triglycerides, or both) in the blood, may be caused by family history of hyperlipidemia), obesity, a high-fat diet, lack of



exercise, moderate to high alcohol consumption, cigarette smoking, poorly controlled diabetes, and an underactive thyroid gland), hereditary hyperlipidemias (type I hyperlipoproteinemia (familial hyperchylomicronemia), type II hyperlipoproteinemia (familial hypercholesterolemia), type III hyperlipoproteinemia, type IV hyperlipoproteinemia, or type V hyperlipoproteinemia), hypo-  
 5 lipoproteinemia, lipidoses (caused by abnormalities in the enzymes that metabolize fats), Gaucher's disease, Niemann-Pick disease, Fabry's disease, Wolman's disease, cerebrotendinous xanthomatosis, sitosterolemia, Refsum's disease, or Tay-Sachs disease.

Kidney disorders may lead to hypertension or hypotension. Examples for kidney problems possibly leading to hypertension are renal artery stenosis, pyelonephritis, glomerulonephritis, kidney  
 10 tumors, polycystic kidney disease, injury to the kidney, or radiation therapy affecting the kidney. Excessive urination may lead to hypotension.

The human PPAR-delta is highly expressed in the following cardiovascular related tissues: heart, heart, heart, heart myocardial infarction, heart myocardial infarction, heart myocardial infarction, pericardium, heart atrium (right), heart atrium (right), heart atrium (left), heart atrium (left), heart  
 15 ventricle (left), heart ventricle (right), heart apex, Purkinje fibers, interventricular septum, aorta valve, mesenteric artery, coronary-artery-endothel-cells, coronary artery smooth muscle primary cells, aortic smooth muscle cells, pulmonary artery smooth muscle cells, aortic endothel cells, HUVEC cells, pulmonary artery endothel cells, iliac artery endothel cells, liver liver cirrhosis, liver lupus disease, liver tumor, adipose, adipose, fetal kidney, kidney, kidney, kidney, kidney  
 20 tumor, renal epithelial cells, HEK 293 cells. Expression in the above mentioned tissues and in particular the differential expression between diseased tissue heart myocardial infarction and healthy tissue demonstrates that the human PPAR-delta or mRNA can be utilized to diagnose of cardiovascular diseases. Additionally the activity of the human PPAR-delta can be modulated to treat cardiovascular diseases.

25 The human PPAR-delta is highly expressed in liver tissues: liver liver cirrhosis, liver lupus disease, liver tumor. Expression in liver tissues demonstrates that the human PPAR-delta or mRNA can be utilized to diagnose of dyslipidemia disorders as an cardiovascular disorder. Additionally the activity of the human PPAR-delta can be modulated to treat - but not limited to - dyslipidemia disorders.

30 The human PPAR-delta is highly expressed in adipose tissues. Expression in adipose demonstrates that the human PPAR-delta or mRNA can be utilized to diagnose of dyslipidemia diseases as an cardiovascular disorder. Additionally the activity of the human PPAR-delta can be modulated to treat - but not limited to - dyslipidemia diseases.

The human PPAR-delta is highly expressed in kidney tissues : fetal kidney, kidney, kidney, kidney, kidney tumor, HEK 293 cells. Expression in kidney tissues demonstrates that the human PPAR-delta or mRNA can be utilized to diagnose of blood pressure disorders as an cardiovascular disorder. Additionally the activity of the human PPAR-delta can be modulated to treat - but not  
 5 limited to - blood pressure disorders as hypertension or hypotension.

### *Hematological Disorders*

Hematological disorders comprise diseases of the blood and all its constituents as well as diseases of organs and tissues involved in the generation or degradation of all the constituents of the blood. They include but are not limited to 1) Anemias, 2) Myeloproliferative Disorders, 3) Hemorrhagic  
 10 Disorders, 4) Leukopenia, 5) Eosinophilic Disorders, 6) Leukemias, 7) Lymphomas, 8) Plasma Cell Dyscrasias, 9) Disorders of the Spleen in the course of hematological disorders. Disorders according to 1) include, but are not limited to anemias due to defective or deficient hem synthesis, deficient erythropoiesis. Disorders according to 2) include, but are not limited to polycythemia vera, tumor-associated erythrocytosis, myelofibrosis, thrombocythemia. Disorders according to 3)  
 15 include, but are not limited to vasculitis, thrombocytopenia, heparin-induced thrombocytopenia, thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, hereditary and acquired disorders of platelet function, hereditary coagulation disorders. Disorders according to 4) include, but are not limited to neutropenia, lymphocytopenia. Disorders according to 5) include, but are not limited to hypereosinophilia, idiopathic hypereosinophilic syndrome. Disorders according to 6)  
 20 include, but are not limited to acute myeloic leukemia, acute lymphoblastic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome. Disorders according to 7) include, but are not limited to Hodgkin's disease, non-Hodgkin's lymphoma, Burkitt's lymphoma, mycosis fungoides cutaneous T-cell lymphoma. Disorders according to 8) include, but are not limited to multiple myeloma, macroglobulinemia, heavy chain diseases. In  
 25 extension of the preceding idiopathic thrombocytopenic purpura, iron deficiency anemia, megaloblastic anemia (vitamin B12 deficiency), aplastic anemia, thalassemia, malignant lymphoma bone marrow invasion, malignant lymphoma skin invasion, hemolytic uremic syndrome, giant platelet disease are considered to be hematological diseases too.

The human PPAR-delta is highly expressed in the following tissues of the hematological system:  
 30 leukocytes (peripheral blood), Jurkat (T-cells), thymus, bone marrow stromal cells, cord blood CD34+ cells, neutrophils cord blood, T-cells peripheral blood CD8+, monocytes peripheral blood CD14+, B-cells peripheral blood CD19+, neutrophils peripheral blood, spleen, spleen liver cirrhosis. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue spleen liver cirrhosis and healthy tissue spleen demonstrates

that the human PPAR-delta or mRNA can be utilized to diagnose of hematological diseases. Additionally the activity of the human PPAR-delta can be modulated to treat hematological disorders.

#### *Gastrointestinal and Liver Diseases*

- 5 Gastrointestinal diseases comprise primary or secondary, acute or chronic diseases of the organs of the gastrointestinal tract which may be acquired or inherited, benign or malignant or metaplastic, and which may affect the organs of the gastrointestinal tract or the body as a whole. They comprise but are not limited to 1) disorders of the esophagus like achalasia, vigorous achalasia, dysphagia, cricopharyngeal incoordination, pre-esophageal dysphagia, diffuse esophageal spasm, globus  
10 sensation, Barrett's metaplasia, gastroesophageal reflux, 2) disorders of the stomach and duodenum like functional dyspepsia, inflammation of the gastric mucosa, gastritis, stress gastritis, chronic erosive gastritis, atrophy of gastric glands, metaplasia of gastric tissues, gastric ulcers, duodenal ulcers, neoplasms of the stomach, 3) disorders of the pancreas like acute or chronic pancreatitis, insufficiency of the exocrine or endocrine tissues of the pancreas like steatorrhea,  
15 diabetes, neoplasms of the exocrine or endocrine pancreas like 3.1) multiple endocrine neoplasia syndrome, ductal adenocarcinoma, cystadenocarcinoma, islet-cell tumors, insulinoma, gastrinoma, carcinoid tumors, glucagonoma, Zollinger-Ellison syndrome, Vipoma syndrome, malabsorption syndrome, 4) disorders of the bowel like chronic inflammatory diseases of the bowel, Crohn's disease, ileus, diarrhea and constipation, colonic inertia, megacolon, malabsorption syndrome,  
20 ulcerative colitis, 4.1) functional bowel disorders like irritable bowel syndrome, 4.2) neoplasms of the bowel like familial polyposis, adenocarcinoma, primary malignant lymphoma, carcinoid tumors, Kaposi's sarcoma, polyps, cancer of the colon and rectum.

- Liver diseases comprise primary or secondary, acute or chronic diseases or injury of the liver which may be acquired or inherited, benign or malignant, and which may affect the liver or the  
25 body as a whole. They comprise but are not limited to disorders of the bilirubin metabolism, jaundice, syndromes of Gilbert's, Crigler-Najjar, Dubin-Johnson and Rotor; intrahepatic cholestasis, hepatomegaly, portal hypertension, ascites, Budd-Chiari syndrome, portal-systemic encephalopathy, fatty liver, steatosis, Reye's syndrome, liver diseases due to alcohol, alcoholic hepatitis or cirrhosis, fibrosis and cirrhosis, fibrosis and cirrhosis of the liver due to inborn errors  
30 of metabolism or exogenous substances, storage diseases, syndromes of Gaucher's, Zellweger's, Wilson's - disease, acute or chronic hepatitis, viral hepatitis and its variants, inflammatory conditions of the liver due to viruses, bacteria, fungi, protozoa, helminths; drug induced disorders of the liver, chronic liver diseases like primary sclerosing cholangitis,  $\alpha_1$ -antitrypsin-deficiency, primary biliary cirrhosis, postoperative liver disorders like postoperative intrahepatic

cholestasis, hepatic granulomas, vascular liver disorders associated with systemic disease, benign or malignant neoplasms of the liver, disturbance of liver metabolism in the new-born or prematurely born.

5 The human PPAR-delta is highly expressed in the following tissues of the gastroenterological system: esophagus tumor, stomach tumor, colon tumor, ileum, ileum tumor, ileum chronic inflammation, rectum, liver liver cirrhosis, liver lupus disease, liver tumor, HEP G2 cells. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue ileum chronic inflammation and healthy tissue , between diseased tissue liver liver cirrhosis and healthy tissue liver, between diseased tissue liver lupus disease and healthy tissue  
10 liver demonstrates that the human PPAR-delta or mRNA can be utilized to diagnose of gastroenterological disorders. Additionally the activity of the human PPAR-delta can be modulated to treat gastroenterological disorders.

#### *Dermatologic Disorders*

15 The skin serves several functions. It's an multi-layered organ system that builds an effective protective cover and regulates body temperature, senses painful and pleasant stimuli, keeps substances from entering the body, and provides a shield from the sun's harmful effects. Skin color, texture, and folds help mark people as individuals. Thus, skin disorders or diseases often have important consequences for physical and mental health. Skin disorders include, but are not limited to the conditions described in the following.

20 Itching (pruritus) is a sensation that instinctively demands scratching, which may be caused by a skin condition or a systemic diseases.

Superficial Skin Disorders affect the uppermost layer of the skin, the stratum corneum or the keratin layer, and it consists of many layers of flattened, dead cells and acts as a barrier to protect the underlying tissue from injury and infection. Disorders of the superficial skin layers involve the  
25 stratum corneum and deeper layers of the epidermis.

Examples of superficial skin disorders are provided in the following.

Dry skin often occurs in people past middle age, severe dry skin (ichthyosis) results from an inherited scaling disease, such as ichthyosis vulgaris or epidermolytic hyperkeratosis. Ichthyosis also results from nonhereditary disorders, such as leprosy, underactive thyroid, lymphoma, AIDS,  
30 and sarcoidosis.



Keratosis pilaris is a common disorder in which dead cells shed from the upper layer of skin and form plugs that fill the openings of hair follicles.

A callus is an area on the stratum corneum or keratin layer, that becomes abnormally thick in response to repeated rubbing.

- 5 A corn is a pea-sized, thickened area of keratin that occurs on the feet.

Psoriasis is a chronic, recurring disease recognizable by silvery scaling bumps and various-sized plaques (raised patches). An abnormally high rate of growth and turnover of skin cells causes the scaling.

- 10 Pityriasis rosea is a mild disease that causes scaly, rose-colored, inflamed skin. Pityriasis rosea is possibly caused by an infectious agent, although none has been identified.

Lichen planus, a recurring itchy disease, starts as a rash of small discrete bumps that then combine and become rough, scaly plaques (raised patches).

Dermatitis (eczema) is an inflammation of the upper layers of the skin, causing blisters, redness, swelling, oozing, scabbing, scaling, and usually itching.

- 15 Forms of dermatitis are contact dermatitis, or chronic dermatitis of the hands and feet, e.g. Pompholyx.

Further examples of dermatitic disorders are atopic dermatitis, seborrheic dermatitis, nummular dermatitis, generalized exfoliative dermatitis, stasis dermatitis, or localized scratch dermatitis (lichen simplex chronicus, neurodermatitis).

- 20 Other skin disorders are caused by inflammation. The skin can break out in a variety of rashes, sores, and blisters. Some skin eruptions can even be life threatening.

Drug rashes are side effects of medications, mainly allergic reactions to medications.

- 25 Toxic epidermal necrolysis is a life-threatening skin disease in which the top layer of the skin peels off in sheets. This condition can be caused by a reaction to a drug, or by some other serious disease.

Erythema multiforme, often caused by herpes simplex is a disorder characterized by patches of red, raised skin that often look like targets and usually are distributed symmetrically over the body.

Erythema nodosum is an inflammatory disorder that produces tender red bumps (nodules) under the skin, most often over the shins but occasionally on the arms and other areas.

Granuloma annulare is a chronic skin condition of unknown cause in which small, firm, raised bumps form a ring with normal or slightly sunken skin in the center.

- 5 Some skin disorders are characterized as blistering diseases. Three autoimmune diseases-- pemphigus, bullous pemphigoid, and dermatitis herpetiformis--are among the most serious.

Pemphigus is an uncommon, sometimes fatal, disease in which blisters (bullae) of varying sizes break out on the skin, the lining of the mouth, and other mucous membranes.

Bullous pemphigoid is an autoimmune disease that causes blistering.

- 10 Dermatitis herpetiformis is an autoimmune disease in which clusters of intensely itchy, small blisters and hive-like swellings break out and persist. In people with the disease, proteins in wheat, rye, barley, and oat products activate the immune system, which attacks parts of the skin and somehow causes the rash and itching.

---

Sweating disorders also belong to skin disorders.

- 15 Prickly heat is an itchy skin rash caused by trapped sweat.

Excessive sweating (hyperhidrosis) may affect the entire surface of the skin, but often it's limited to the palms, soles, armpits, or groin. The affected area is often pink or bluish white, and in severe cases the skin may be cracked, scaly, and soft, especially on the feet.

- 20 Skin disorders can affect the sebaceous glands. The sebaceous glands, which secrete oil onto the skin, lie in the dermis, the skin layer just below the surface layer (epidermis). Sebaceous gland disorders include acne, rosacea, perioral dermatitis, and sebaceous cysts.

Acne is a common skin condition in which the skin pores become clogged, leading to pimples and inflamed, infected abscesses (collections of pus). Acne tends to develop in teenagers.

Acne is further subdivided in superficial acne or deep acne.

- 25 Rosacea is a persistent skin disorder that produces redness, tiny pimples, and broken blood vessels, usually on the central area of the face.

Perioral dermatitis is a red, often bumpy rash around the mouth and on the chin.

A sebaceous cyst (keratinous cyst) is a slow-growing bump containing dead skin, skin excretions, and other skin particles. These cysts may be small and can appear anywhere.

Hair Disorders also are skin disorders. Hair disorders include excessive hairiness, baldness, and ingrown beard hairs.

- 5 The skin can be infected by bacteria. Bacterial skin infections can range in seriousness from minor acne to a life-threatening condition, such as staphylococcal scalded skin syndrome. The most common bacterial skin infections are caused by Staphylococcus and Streptococcus. Risk factors for skin infections are for example diabetes, AIDS or skin lesions.

- 10 Impetigo is a skin infection, caused by Staphylococcus or Streptococcus, leading to the formation of small pus-filled blisters (pustules).

Folliculitis is an inflammation of the hair follicles caused by infection with Staphylococcus. The infection damages the hairs, which can be easily pulled out.

Boils (furuncles) are large, tender, swollen, raised areas caused by staphylococcal infection around hair follicles.

- 15 Carbuncles are clusters of boils that result in extensive sloughing of skin and scar formation. Carbuncles develop and heal more slowly than single boils and may lead to fever and fatigue.

Erysipelas is a skin infection caused by Streptococcus. A shiny, red, slightly swollen, tender rash develops, often with small blisters. Lymph nodes around the infected area may become enlarged and painful.

- 20 Cellulitis is a spreading infection in, and sometimes beneath, the deep layers of the skin. Cellulitis most often results from a streptococcal infection or a staphylococcal infection. However, many other bacteria can also cause cellulitis.

Paronychia is an infection around the edge of a fingernail or toenail. Paronychia can be caused by many different bacteria, including Pseudomonas and Proteus, and by fungi, such as Candida.

- 25 Staphylococcal scalded skin syndrome is a widespread skin infection that can lead to toxic shock syndrome, in which the skin peels off as though burned. Certain types of staphylococci produce a toxic substance that causes the top layer of skin (epidermis) to split from the rest of the skin.

Erythrasma is an infection of the top layers of the skin by the bacterium Corynebacterium minutissimum.

Skin infections are often caused by fungi. Fungi that infect the skin (dermatophytes) live only in the dead, topmost layer (stratum corneum) and don't penetrate deeper. Some fungal infections cause no symptoms or produce only a small amount of irritation, scaling, and redness. Other fungal infections cause itching, swelling, blisters, and severe scaling.

- 5 Ringworm is a fungal skin infection caused by several different fungi and generally classified by its location on the body.

Examples are Athlete's foot (foot ringworm, caused by either Trichophyton or Epidermophyton), jock itch (groin ringworm, can be caused by a variety of fungi and yeasts), scalp ringworm, caused by Trichophyton or Microsporum), nail ringworm and body ringworm (caused by Trichophyton).

- 10 Candidiasis (yeast infection, moniliasis) is an infection by the yeast Candida. Candida usually infects the skin and mucous membranes, such as the lining of the mouth and vagina. Rarely, it invades deeper tissues as well as the blood, causing life-threatening systemic candidiasis. The following types of candida infections can be distinguished: Infections in skinfolds (intertriginous infections), vaginal and penile candida infections (vulvovaginitis), thrush, Perlèche (candida infection at the corners of the mouth), candidal paronychia (candida growing in the nail beds, produces painful swelling and pus).

Tinea versicolor is a fungal infection that causes white to light brown patches on the skin.

The skin can also be affected by parasites, mainly tiny insects or worms.

- 20 Scabies is a mite infestation that produces tiny reddish pimples and severe itching. Scabies is caused by the itch mite *Sarcoptes scabiei*.

Lice infestation (pediculosis) causes intense itching and can affect almost any area of the skin. Head lice and pubic lice are two different species.

- 25 Creeping eruption (cutaneous larva migrans) is a hookworm infection transmitted from warm, moist soil to exposed skin. The infection is caused by a hookworm that normally inhabits dogs and cats.

- 30 Many types of viruses invade the skin. The medically important ones cause warts and cold sores (fever blisters) on the lip. Warts are caused by the papillomavirus, and cold sores are caused by the herpes simplex virus. Another important group of viruses that infect the skin belongs to the poxvirus family. Chickenpox remains a common childhood infection. A poxvirus also causes molluscum contagiosum, which is an infection of the skin by a poxvirus that causes skin-colored, smooth, waxy bumps.



Sunlight can cause severe skin damage. Sunburn results from an overexposure to ultraviolet B (UVB) rays. Some sunburned people develop a fever, chills, and weakness, and those with very bad sunburns even may go into shock--low blood pressure, and fainting.

5 People who are in the sun a lot have an increased risk of skin cancers, including squamous cell carcinoma, basal cell carcinoma, and to some degree, malignant melanoma.

Drugs, among other causes, can cause skin photosensitivity reactions which can occur after only a few minutes of sun exposure. These reactions include redness, peeling, hives, blisters, and thickened, scaling patches (photosensitivity).

Some skin disorders are characterized as Pigment Disorders.

10 Albinism is a rare, inherited disorder in which no melanin is formed.

Vitiligo is a condition in which a loss of melanocytes results in smooth, whitish patches of skin, which may occur after unusual physical trauma and tends to occur with certain other diseases, including Addison's disease, diabetes, pernicious anemia, and thyroid disease.

---

Tinea versicolor is a fungal infection of the skin that sometimes results in hyperpigmentation.

15 Melasma appears on the face (usually the forehead, cheeks, temples, and jaws) as a roughly symmetric group of dark brown patches of pigmentation that are often clearly delineated.

Skin growths, which are abnormal accumulations of different types of cells, may be present at birth or develop later. Noncancerous (benign) growth and cancerous (malignant) growth types are distinguished.

20 Moles (nevi) are small, usually dark, skin growths that develop from pigment-producing cells in the skin (melanocytes). Most moles are harmless. However, noncancerous moles can develop into malignant melanoma.

Skin tags are soft, small, flesh-colored or slightly darker skin flaps that appear mostly on the neck, in the armpits, or in the groin.

25 Lipomas are soft deposits of fatty material that grow under the skin, causing round or oval lumps.

Angiomas are collections of abnormally dense blood or lymph vessels that are usually located in and below the skin and that cause red or purple discolorations.

Examples of angiomas are port-wine stains, strawberry marks, cavernous hemangiomas, spider angiomas, and lymphangiomas.

Pyogenic granulomas are scarlet, brown, or blue-black slightly raised areas caused by increased growth of capillaries (the smallest blood vessels) and swelling of the surrounding tissue.

- 5    Seborrheic keratoses (sometimes called seborrheic warts) are flesh-colored, brown, or black growths that can appear anywhere on the skin.

Dermatofibromas are small, red-to-brown bumps (nodules) that result from an accumulation of fibroblasts, the cells that populate the soft tissue under the skin.

- 10   Keratoacanthomas are round, firm, usually flesh-colored growths that have an unusual central crater containing a pasty material.

Keloids are smooth, shiny, slightly pink, often dome-shaped, proliferative growths of fibrous tissue that form over areas of injury or over surgical wounds.

Skin cancer is the most common form of cancer, but most types of skin cancers are curable.

Basal cell carcinoma is a cancer that originates in the lowest layer of the epidermis.

- 15   Squamous cell carcinoma is cancer that originates in the middle layer of the epidermis.

Bowen's disease is a form of squamous cell carcinoma that's confined to the epidermis and hasn't yet invaded the underlying dermis.

Melanoma is a cancer that originates in the pigment-producing cells of the skin (melanocytes).

Kaposi's sarcoma is a cancer that originates in the blood vessels, usually of the skin.

- 20   Paget's disease is a rare type of skin cancer that looks like an inflamed, reddened patch of skin (dermatitis); it originates in glands in or under the skin.

The human PPAR-delta is highly expressed in the following dermatological tissues: skin. The expression in the above mentioned tissues demonstrates that the human PPAR-delta or mRNA can be utilized to diagnose of dermatological diseases. Additionally the activity of the human PPAR-

- 25   delta can be modulated to treat those diseases.

*Musculoskeletal Diseases*

Components of the musculoskeletal system are skeleton, muscles, tendons, ligaments, and other components of joints. Disorders of the musculoskeletal system often cause chronic pain and physical disability. They range from injuries, infections, inflammation or other types of disorders.

5 Examples of musculoskeletal disorders are presented in the following.

Examples are osteoporosis, postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis, idiopathic juvenile osteoporosis, Paget's disease of the bone, osteochondromas (osteocartilaginous exostoses), tumors of the bone (benign chondromas, chondroblastomas, chondromyxoid fibromas, osteoid osteomas, giant cell tumors of the bone, multiple myeloma, 10 osteosarcoma (osteogenic sarcoma), fibrosarcomas and malignant fibrous histiocytomas, chondrosarcomas, Ewing's tumor (Ewing's sarcoma), malignant lymphoma of bone (reticulum cell sarcoma, metastatic tumors of the bone), osteoarthritis, and gout and Pseudogout.

Examples of disorders of joints and connective tissue are rheumatoid arthritis, psoriatic arthritis, discoid lupus erythematosus, systemic lupus erythematosus, scleroderma (systemic sclerosis), 15 Sjögren's syndrome, connective tissue disease, polymyositis and dermatomyositis, relapsing polychondritis, vasculitis, polyarteritis nodosa, polymyalgia rheumatica, temporal arteritis, Wegener's granulomatosis, Reiter's syndrome, Behçet's syndrome, ankylosing spondylitis, or Charcot's joints (neuropathic joint disease).

Examples for bone and joint infections are osteomyelitis, and infectious arthritis.

20 Examples of disorders of muscles, bursas, and tendons are spasmodic torticollis, fibromyalgia syndromes (myofascial pain syndromes, fibromyositis), bursitis, tendinitis and tenosynovitis.

Foot problems are, for example ankle sprain, foot fractures, heel spurs, Sever's disease, posterior achilles tendon bursitis, anterior achilles tendon bursitis, posterior tibial neuralgia, pain in the ball of the foot (caused by damage to the nerves between the toes or to the joints between the toes and 25 foot), onychomycosis, or nail discoloration.

The human PPAR-delta is highly expressed in the following muscle/skeleton tissues: skeletal muscle, cartilage, bone connective tissue, adipose, adipose, fetal adipose. The expression in muscle/skeleton tissues demonstrates that the human PPAR-delta or mRNA can be utilized to diagnose of diseases of the muscle/skeleton system. Additionally the activity of the human PPAR- 30 delta can be modulated to treat those diseases.

*Cancer Disorders*

Cancer disorders within the scope of this definition comprise any disease of an organ or tissue in mammals characterized by poorly controlled or uncontrolled multiplication of normal or abnormal cells in that tissue and its effect on the body as a whole. Cancer diseases within the scope of the definition comprise benign neoplasms, dysplasias, hyperplasias as well as neoplasms showing metastatic growth or any other transformations like e.g. leukoplakias which often precede a breakout of cancer. Cells and tissues are cancerous when they grow more rapidly than normal cells, displacing or spreading into the surrounding healthy tissue or any other tissues of the body described as metastatic growth, assume abnormal shapes and sizes, show changes in their nucleocytoplasmatic ratio, nuclear polychromasia, and finally may cease. Cancerous cells and tissues may affect the body as a whole when causing paraneoplastic syndromes or if cancer occurs within a vital organ or tissue, normal function will be impaired or halted, with possible fatal results. The ultimate involvement of a vital organ by cancer, either primary or metastatic, may lead to the death of the mammal affected. Cancer tends to spread, and the extent of its spread is usually related to an individual's chances of surviving the disease. Cancers are generally said to be in one of three stages of growth: early, or localized, when a tumor is still confined to the tissue of origin, or primary site; direct extension, where cancer cells from the tumour have invaded adjacent tissue or have spread only to regional lymph nodes; or metastasis, in which cancer cells have migrated to distant parts of the body from the primary site, via the blood or lymph systems, and have established secondary sites of infection. Cancer is said to be malignant because of its tendency to cause death if not treated. Benign tumors usually do not cause death, although they may if they interfere with a normal body function by virtue of their location, size, or paraneoplastic side effects. Hence benign tumors fall under the definition of cancer within the scope of this definition as well. In general, cancer cells divide at a higher rate than do normal cells, but the distinction between the growth of cancerous and normal tissues is not so much the rapidity of cell division in the former as it is the partial or complete loss of growth restraint in cancer cells and their failure to differentiate into a useful, limited tissue of the type that characterizes the functional equilibrium of growth of normal tissue. Cancer tissues may express certain molecular receptors and probably are influenced by the host's susceptibility and immunity and it is known that certain cancers of the breast and prostate, for example, are considered dependent on specific hormones for their existence. The term "cancer" under the scope of the definition is not limited to simple benign neoplasia but comprises any other benign and malign neoplasia like 1) Carcinoma, 2) Sarcoma, 3) Carcinosarcoma, 4) Cancers of the blood-forming tissues, 5) tumors of nerve tissues including the brain, 6) cancer of skin cells. Cancer according to 1) occurs in epithelial tissues, which cover the outer body (the skin) and line mucous membranes and the inner cavitory structures of organs e.g. such as the breast, lung, the respiratory and gastrointestinal tracts, the endocrine glands, and the



genitourinary system. Ductal or glandular elements may persist in epithelial tumors, as in adenocarcinomas like e.g. thyroid adenocarcinoma, gastric adenocarcinoma, uterine adenocarcinoma. Cancers of the pavement-cell epithelium of the skin and of certain mucous membranes, such as e.g. cancers of the tongue, lip, larynx, urinary bladder, uterine cervix, or penis, may be

5 termed epidermoid or squamous-cell carcinomas of the respective tissues and are in the scope of the definition of cancer as well. Cancer according to 2) develops in connective tissues, including fibrous tissues, adipose (fat) tissues, muscle, blood vessels, bone, and cartilage like e.g. osteogenic sarcoma; liposarcoma, fibrosarcoma, synovial sarcoma. Cancer according to 3) is cancer that develops in both epithelial and connective tissue. Cancer disease within the scope of this definition

10 may be primary or secondary, whereby primary indicates that the cancer originated in the tissue where it is found rather than was established as a secondary site through metastasis from another lesion. Cancers and tumor diseases within the scope of this definition may be benign or malign and may affect all anatomical structures of the body of a mammal. By example but not limited to they comprise cancers and tumor diseases of I) the bone marrow and bone marrow derived cells

15 (leukemias), II) the endocrine and exocrine glands like e.g. thyroid, parathyroid, pituitary, adrenal glands, salivary glands, pancreas III) the breast, like e.g. benign or malignant tumors in the mammary glands of either a male or a female, the mammary ducts, adenocarcinoma, medullary carcinoma, comedo carcinoma, Paget's disease of the nipple, inflammatory carcinoma of the young woman, IV) the lung, V) the stomach, VI) the liver and spleen, VII) the small intestine, VIII) the

20 colon, IX) the bone and its supportive and connective tissues like malignant or benign bone tumour, e.g. malignant osteogenic sarcoma, benign osteoma, cartilage tumors; like malignant chondrosarcoma or benign chondroma; bone marrow tumors like malignant myeloma or benign eosinophilic granuloma, as well as metastatic tumors from bone tissues at other locations of the body; X) the mouth, throat, larynx, and the esophagus, XI) the urinary bladder and the internal and

25 external organs and structures of the urogenital system of male and female like ovaries, uterus, cervix of the uterus, testes, and prostate gland, XII) the prostate, XIII) the pancreas, like ductal carcinoma of the pancreas; XIV) the lymphatic tissue like lymphomas and other tumors of lymphoid origin, XV) the skin, XVI) cancers and tumor diseases of all anatomical structures belonging to the respiration and respiratory systems including thoracal muscles and linings, XVII)

30 primary or secondary cancer of the lymph nodes XVIII) the tongue and of the bony structures of the hard palate or sinuses, XVIV) the mouth, cheeks, neck and salivary glands, XX) the blood vessels including the heart and their linings, XXI) the smooth or skeletal muscles and their ligaments and linings, XXII) the peripheral, the autonomous, the central nervous system including the cerebellum, XXIII) the adipose tissue.

35 The human PPAR-delta is highly expressed in the following cancer tissues: HUVEC cells, thyroid tumor, esophagus tumor, stomach tumor, colon tumor, ileum tumor, liver tumor, HEP G2 cells,

Jurkat (T-cells), glial tumor H4 cells, lung tumor, uterus tumor, ovary tumor, breast tumor, prostate tumor, kidney tumor, HEK 293 cells. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue thyroid tumor and healthy tissue thyroid, between diseased tissue esophagus tumor and healthy tissue esophagus, between diseased tissue stomach tumor and healthy tissue stomach, between diseased tissue colon tumor and healthy tissue colon, between diseased tissue ileum tumor and healthy tissue , between diseased tissue liver tumor and healthy tissue liver, between diseased tissue HEP G2 cells and healthy tissue liver, between diseased tissue Jurkat (T-cells) and healthy tissue T-cells peripheral blood CD4+, between diseased tissue lung tumor and healthy tissue lung, between diseased tissue uterus tumor and healthy tissue uterus, between diseased tissue ovary tumor and healthy tissue ovary, between diseased tissue breast tumor and healthy tissue breast, between diseased tissue prostate tumor and healthy tissue prostate, between diseased tissue kidney tumor and healthy tissue kidney, between diseased tissue HEK 293 cells and healthy tissue kidney demonstrates that the human PPAR-delta or mRNA can be utilized to diagnose of cancer. Additionally the activity of the human PPAR-delta can be modulated to treat cancer.

#### *Inflammatory Diseases*

Inflammatory diseases comprise diseases triggered by cellular or non-cellular mediators of the immune system or tissues causing the inflammation of body tissues and subsequently producing an acute or chronic inflammatory condition. Examples for such inflammatory diseases are hypersensitivity reactions of type I – IV, for example but not limited to hypersensitivity diseases of the lung including asthma, atopic diseases, allergic rhinitis or conjunctivitis, angioedema of the lids, hereditary angioedema, antireceptor hypersensitivity reactions and autoimmune diseases, Hashimoto's thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, pemphigus, myasthenia gravis, Grave's and Raynaud's disease, type B insulin-resistant diabetes, rheumatoid arthritis, psoriasis, Crohn's disease, scleroderma, mixed connective tissue disease, polymyositis, sarcoidosis, glomerulonephritis, acute or chronic host versus graft reactions.

The human PPAR-delta is highly expressed in the following tissues of the immune system and tissues responsive to components of the immune system as well as in the following tissues responsive to mediators of inflammation: ileum chronic inflammation, liver liver cirrhosis, leukocytes (peripheral blood), neutrophils cord blood, neutrophils peripheral blood, spleen liver cirrhosis. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue ileum chronic inflammation and healthy tissue , between diseased tissue liver liver cirrhosis and healthy tissue liver, between diseased tissue spleen liver cirrhosis and healthy tissue spleen demonstrates that the human PPAR-delta or mRNA can be

utilized to diagnose of inflammatory diseases. Additionally the activity of the human PPAR-delta can be modulated to treat inflammatory diseases.

### *Disorders Related to Urology*

5 Genitourinary disorders comprise benign and malign disorders of the organs constituting the genitourinary system of female and male, renal diseases like acute or chronic renal failure, immunologically mediated renal diseases like renal transplant rejection, lupus nephritis, immune complex renal diseases, glomerulopathies, nephritis, toxic nephropathy, obstructive uropathies like benign prostatic hyperplasia (BPH), neurogenic bladder syndrome, urinary incontinence like urge-, stress-, or overflow incontinence, pelvic pain, and erectile dysfunction.

10 The human PPAR-delta is highly expressed in the following urological tissues: spinal cord, prostate, prostate, prostate, prostate BPH, prostate tumor, bladder, bladder, bladder, ureter, fetal kidney, kidney, kidney, kidney, kidney tumor, renal epithelial cells, HEK 293 cells. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue prostate BPH and healthy tissue prostate demonstrates that the human PPAR-delta or mRNA can  
15 be utilized to diagnose of urological disorders. Additionally the activity of the human PPAR-delta  
can be modulated to treat urological disorders.

The human PPAR-delta is highly expressed in spinal cord tissues: spinal cord. Expression in spinal cord tissues demonstrates that the human PPAR-delta or mRNA can be utilized to diagnose of incontinence as an urological disorder. The spinal cord tissues are involved in the neuronal  
20 regulation of the urological system. Additionally the activity of the human PPAR-delta can be modulated to treat - but not limited to - incontinence.

### *Diseases of the Reproductive System*

Disorders of the male reproductive system include but are not limited to balanoposthitis, balanitis xerotica obliterans, phimosis, paraphimosis, erythroplasia of Queyrat, skin cancer of the penis,  
25 Bowen's and Paget's diseases, syphilis, herpes simplex infections, genital warts, molluscum contagiosum, priapism, peyronie's disease, benign prostatic hyperplasia (BPH), prostate cancer, prostatitis, testicular cancer, testicular torsion, inguinal hernia, epididymo-orchitis, mumps, hydroceles, spermatoceles, or varicoceles.

Impotence (erectile dysfunction) may results from vascular impairment, neurologic disorders,  
30 drugs, abnormalities of the penis, or psychologic problems.



Examples of disorders of the female reproductive include premature menopause, pelvic pain, vaginitis, vulvitis, vulvovaginitis, pelvic inflammatory disease, fibroids, menstrual disorders (premenstrual syndrome (PMS), dysmenorrhea, amenorrhea, primary amenorrhea, secondary amenorrhea, menorrhagia, hypomenorrhea, polymenorrhea, oligomenorrhea, metrorrhagia, 5 menometrorrhagia, Postmenopausal bleeding), bleeding caused by a physical disorder, dysfunctional uterine bleeding, polycystic ovary syndrome (Stein-Leventhal syndrome), endometriosis, cancer of the uterus, cancer of the cervix, cancer of the ovaries, cancer of the vulva, cancer of the vagina, cancer of the fallopian tubes, or hydatidiform mole.

10 Infertility may be caused by problems with sperm, ovulation, the fallopian tubes, and the cervix as well as unidentified factors.

Complications of pregnancy include miscarriage and stillbirth, ectopic pregnancy, anemia, Rh incompatibility, problems with the placenta, excessive vomiting, preeclampsia, eclampsia, and skin rashes (e.g. herpes gestationis, urticaria of pregnancy) as well as preterm labor and premature rupture of the membranes.

15 Breast disorders may be noncancerous (benign) or cancerous (malignant). Examples of breast disorders are but are not limited to breast pain, cysts, fibrocystic breast disease, fibrous lumps, nipple discharge, breast infection, breast cancer (ductal carcinoma, lobular carcinoma, medullary carcinoma, tubular carcinoma, and inflammatory breast cancer), Paget's disease of the nipple or Cystosarcoma phyllodes.

20 The human PPAR-delta is highly expressed in the following tissues of the reproduction system: placenta, uterus tumor, ovary, ovary tumor, breast, breast tumor, mammary gland. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue breast tumor and healthy tissue breast demonstrates that the human PPAR-delta or mRNA can be utilized to diagnose of reproduction disorders. Additionally the activity of the human PPAR-delta 25 can be modulated to treat reproduction disorders.

### *Metabolic Disorders*

Metabolic diseases are defined as conditions which result from an abnormality in any of the chemical or biochemical transformations and their regulating systems essential to producing energy, to regenerating cellular constituents, to eliminating unneeded products arising from these processes, and to regulate and maintain homeostasis in a mammal regardless of whether acquired 30 or the result of a genetic transformation. Depending on which metabolic pathway is involved, a single defective transformation or disturbance of its regulation may produce consequences that are



narrow, involving a single body function, or broad, affecting many organs, organ-systems or the body as a whole. Diseases resulting from abnormalities related to the fine and coarse mechanisms that affect each individual transformation, its rate and direction or the availability of substrates like amino acids, fatty acids, carbohydrates, minerals, cofactors, hormones, regardless whether they are  
5 inborn or acquired, are well within the scope of the definition of a metabolic disease according to this application.

Metabolic diseases often are caused by single defects in particular biochemical pathways, defects that are due to the deficient activity of individual enzymes or molecular receptors leading to the regulation of such enzymes. Hence in a broader sense disturbances of the underlying genes, their  
10 products and their regulation lie well within the scope of this definition of a metabolic disease. For example, but not limited to, metabolic diseases may affect 1) biochemical processes and tissues ubiquitous all over the body, 2) the bone, 3) the nervous system, 4) the endocrine system, 5) the muscle including the heart, 6) the skin and nervous tissue, 7) the urogenital system, 8) the homeostasis of body systems like water and electrolytes. For example, but not limited to,  
15 metabolic diseases according to 1) comprise obesity, amyloidosis, disturbances of the amino acid metabolism like branched chain disease, hyperaminoacidemia, hyperaminoaciduria, disturbances of the metabolism of urea, hyperammonemia, mucopolysaccharidoses e.g. Maroteaux-Lamy syndrom, storage diseases like glycogen storage diseases and lipid storage diseases, glycogenesis diseases like Cori's disease, malabsorption diseases like intestinal carbohydrate malabsorption,  
20 oligosaccharidase deficiency like maltase-, lactase-, sucrase-insufficiency, disorders of the metabolism of fructose, disorders of the metabolism of galactose, galactosaemia, disturbances of carbohydrate utilization like diabetes, hypoglycemia, disturbances of pyruvate metabolism, hypolipidemia, hypolipoproteinemia, hyperlipidemia, hyperlipoproteinemia, carnitine or carnitine acyltransferase deficiency, disturbances of the porphyrin metabolism, porphyrias, disturbances of  
25 the purine metabolism, lysosomal diseases, metabolic diseases of nerves and nervous systems like gangliosidoses, sphingolipidoses, sulfatidoses, leucodystrophies, Lesch-Nyhan syndrome. For example, but not limited to, metabolic diseases according to 2) comprise osteoporosis, osteomalacia like osteoporosis, osteopenia, osteogenesis imperfecta, osteopetrosis, osteonecrosis, Paget's disease of bone, hypophosphatemia. For example, but not limited to, metabolic diseases  
30 according to 3) comprise cerebellar dysfunction, disturbances of brain metabolism like dementia, Alzheimer's disease, Huntington's chorea, Parkinson's disease, Pick's disease, toxic encephalopathy, demyelinating neuropathies like inflammatory neuropathy, Guillain-Barré syndrome. For example, but not limited to, metabolic diseases according to 4) comprise primary and secondary metabolic disorders associated with hormonal defects like any disorder stemming  
35 from either an hyperfunction or hypofunction of some hormone-secreting endocrine gland and any

combination thereof. They comprise Sipple's syndrome, pituitary gland dysfunction and its effects on other endocrine glands, such as the thyroid, adrenals, ovaries, and testes, acromegaly, hyper- and hypothyroidism, euthyroid goiter, euthyroid sick syndrome, thyroiditis, and thyroid cancer, over- or underproduction of the adrenal steroid hormones, adrenogenital syndrome, Cushing's syndrome, Addison's disease of the adrenal cortex, Addison's pernicious anemia, primary and secondary aldosteronism, diabetes insipidus, carcinoid syndrome, disturbances caused by the dysfunction of the parathyroid glands, pancreatic islet cell dysfunction, diabetes, disturbances of the endocrine system of the female like estrogen deficiency, resistant ovary syndrome. For example, but not limited to, metabolic diseases according to 5) comprise muscle weakness, myotonia, Duchenne's and other muscular dystrophies, dystrophia myotonica of Steinert, mitochondrial myopathies like disturbances of the catabolic metabolism in the muscle, carbohydrate and lipid storage myopathies, glycogenoses, myoglobinuria, malignant hyperthermia, polymyalgia rheumatica, dermatomyositis, primary myocardial disease, cardiomyopathy. For example, but not limited to, metabolic diseases according to 6) comprise disorders of the ectoderm, neurofibromatosis, scleroderma and polyarteritis, Louis-Bar syndrome, von Hippel-Lindau disease, Sturge-Weber syndrome, tuberous sclerosis, amyloidosis, porphyria. For example, but not limited to, metabolic diseases according to 7) comprise sexual dysfunction of the male and female. For example, but not limited to, metabolic diseases according to 8) comprise confused states and seizures due to inappropriate secretion of antidiuretic hormone from the pituitary gland, Liddle's syndrome, Bartter's syndrome, Fanconi's syndrome, renal electrolyte wasting, diabetes insipidus.

The human PPAR-delta is highly expressed in the following tissues of metabolic related tissues : adipose. The expression in the above mentioned tissues demonstrates that the human PPAR-delta or mRNA can be utilized to diagnose of metabolic diseases. Additionally the activity of the human PPAR-delta can be modulated to treat metabolic diseases.

## 25 *Infections*

Certain bacteria, virusses, fungi and parasites are able to establish an infection of the human body. This invention relates to treatment of infectious diseases. In the following, examples of pathogens potentially leading to infections and infectious diseases are presented. The diseases mentioned serve as examples, the scope of the invention is not limited to infections presented here.

30 Examples of infections of the skin and underlying tissue are: cellulitis, necrotizing fasciitis, skin gangrene, lymphadenitis, acute lymphangitis, impetigo, skin abscesses, folliculitis, boils (furuncles), erysipelas, carbuncles (clusters of boils and skin abscesses), staphylococcal scalded skin syndrome, erythrasma or paronychia (can be caused by many bacteria and fungi). Most of

these are bacterial infections. The most common bacterial skin infections are caused by Staphylococcus and Streptococcus.

5 Skin infections caused by fungi are ringworm, a fungal skin infection caused by several different fungi and generally classified by its location on the body. Examples are Athlete's foot (foot ringworm, caused by either Trichophyton or Epidermophyton), jock itch (groin ringworm, can be caused by a variety of fungi and yeasts), scalp ringworm, caused by Trichophyton or Microsporum), nail ringworm and body ringworm (caused by Trichophyton).

10 Candidiasis (yeast infection, moniliasis) is an infection by the yeast Candida. The following types of candida infections can be distinguished: Infections in skinfolds (intertriginous infections), vaginal and penile candida infections (vulvovaginitis), thrush, Perlèche (candida infection at the corners of the mouth), candidal paronychia (candida growing in the nail beds, produces painful swelling and pus). Candida can also lead to generalized systemic infections especially in the immunocompromised host.

Tinea versicolor is a fungal infection that causes white to light brown patches on the skin.

15 The skin can also be affected by parasites, mainly tiny insects or worms. Examples are scabies (mite infestation), lice infestation (pediculosis, head lice and pubic lice are two different species), or creeping eruption (cutaneous larva migrans, a hookworm infection).

20 Many types of viruses invade the skin. Examples are papillomaviruses (causing warts), herpes simplex virus (causing e.g. cold sores), or members of the poxvirus family (molluscum contagiosum (infection of the skin, causing skin-colored, smooth, waxy bumps).

Abscesses are accumulation of pus, usually caused by a bacterial infection. Examples are abdominal abscesses, head and neck abscesses, muscle abscesses, or hand Abscesses.

25 Bacteremia, the presence of bacteria in the bloodstream, is common and usually causes no symptoms. Most bacteria that enter the bloodstream are rapidly removed by white blood cells. Sometimes, however, there are too many bacteria to be removed easily, and an infection called sepsis develops, causing severe symptoms. In some cases, sepsis leads to a life-threatening condition called septic shock.

30 Bacilli are a type of bacteria classified according to their distinctive rod-like shape. Bacteria are either spherical (coccal), rod-like (bacillary), or spiral/helical (spirochetal) in shape. Gram-positive or gram-negative bacilli are distinguished



Examples of gram-positive bacillary infections are erysipelothraxis (caused by *Erysipelothrix rhusiopathiae*), listeriosis (caused by *Listeria monocytogenes*), and anthrax (caused by *Bacillus anthracis*). Within anthrax, pulmonary anthrax, gastrointestinal anthrax and anthrax skin sores can be distinguished.

- 5 Examples of gram-negative bacillary infections are *Hemophilus* infections, *Hemophilus influenzae* infections, *Hemophilus ducreyi* (causes chancroid), Brucellosis (undulant, Malta, Mediterranean, or Gibraltar fever, caused by *Brucella* bacteria), tularemia (rabbit fever, deer fly fever, caused by *Francisella tularensis*), plague (black death, caused by *Yersinia pestis*, bubonic plague, pneumonic plague, septicemic plague and *pestis minor* are distinguished), cat-scratch disease (caused by the
- 10 bacterium *Bartonella henselae*), *Pseudomonas* infections (especially *Pseudomonas aeruginosa*), infections of the gastrointestinal tract or blood caused by *Campylobacter* bacteria (e.g. *Campylobacter pylori* [*Helicobacter pylori*]), cholera (infection of the small intestine caused by *Vibrio cholerae*), infections with other *Vibrio* spp., Enterobacteriaceae infections (cause e.g. infections of the gastrointestinal tract, members of the group are *Salmonella*, *Shigella*, *Escherichia*,
- 15 *Klebsiella*, *Enterobacter*, *Serratia*, *Proteus*, *Morganella*, *Providencia*, and *Yersinia*), *Klebsella pneumonia* infections (severe lung infection), typhoid fever (caused by *Salmonella typhi*), nontyphoidal *Salmonella* infections, or Shigellosis (bacillary dysentery, an intestinal infection caused by *Shigella* bacteria).

- Bacteria that have a spherical shape are called cocci. Cocci that can cause infection in humans
- 20 include staphylococci, streptococci (group A streptococci, group B streptococci, groups C and G streptococci, group D streptococci and enterococci), pneumococci (cause e.g. pneumonia, thoracic empyema, bacterial meningitis, bacteremia, pneumococcal endocarditis, peritonitis, pneumococcal arthritis or otitis media), and meningococci. Toxic shock syndrome is an infection usually caused by staphylococci, which may rapidly worsen to severe, untreatable shock. Meningococci (*Neisseria*
- 25 meningitidis) may cause infection of the layers covering the brain and spinal cord (meningitis). *Neisseria gonorrhoeae* cause gonorrhea, a sexually transmitted disease.

Spirochetal Infections are infections with spirochetes, corkscrew-shaped bacteria. Examples include infections with *Treponema*, *Borrelia*, *Leptospira*, and *Spirillum*.

- Treponematoses (e.g. yaws, pinta) are caused by a spirochete that is indistinguishable from
- 30 *Treponema pallidum* (causes syphilis).

Relapsing fever (tick fever, recurrent fever, or famine fever) is a disease caused by several strains of *Borrelia* bacteria.



Lyme disease (transmitted by deer ticks) is caused by the spirochete *Borrelia burgdorferi*.

Other examples for infections with spirochetes are Leptospirosis (a group of infections including Weil's syndrome, infectious (spirochetal) jaundice, and canicola fever), or rat-bite fever).

5 Disease-causing anaerobic bacteria include clostridia, peptococci, and peptostreptococci. Other examples are *Bacteroides fragilis*, *Prevotella melaninogenica* and *Fusobacterium*. Infections with anaerobic bacteria include dental abscesses, jawbone infections, periodontal disease, chronic sinusitis and middle ear infection, and abscesses in the brain, spinal cord, lung, abdominal cavity, liver, uterus, genitals, skin, and blood vessels. Examples for Clostridial infections tetanus (lockjaw, caused by the bacterium *Clostridium tetani*), or Actinomycosis (a chronic infection  
10 caused mainly by *Actinomyces israelii*).

Tuberculosis and leprosy are caused by *Mycobacteria*. Tuberculosis is caused by the airborne bacterium *Mycobacterium tuberculosis*, *M. bovis*, or *M. africanum*. Leprosy (Hansen's disease) is caused by the bacterium *Mycobacterium leprae*.

15 Rickettsial infections are also known. Examples of diseases caused by Rickettsiae or Ehrlichiae are murine typhus (caused by *Rickettsia typhi*), Rocky Mountain spotted fever (caused by *Rickettsia rickettsii*), epidemic typhus (*Rickettsia prowazekii*), scrub typhus (*Rickettsia tsutsugamushi*), Ehrlichiosis (*Ehrlichia canis* or closely related species), Rickettsial-pox, (*Rickettsia akari*), Q fever (*Coxiella burnetii*), or trench fever (*Bartonella quintana*).

20 A parasite is an organism, such as a single-celled animal (protozoan) or worm, that survives by living inside another, usually much larger, organism. Examples for parasitic infections are Amebiasis (caused by *Entamoeba histolytica*), Giardiasis (*Giardia lamblia*), Malaria (*Plasmodium*), Toxoplasmosis (*Toxoplasma gondii*), Babesiosis (*Babesia* parasites), Trichuriasis (*Trichuris trichiura*, an intestinal roundworm), Ascariasis (*Ascaris lumbricoides*), Hookworm Infection (*Ancylostoma duodenale* or *Necator americanus*), Trichinosis (*Trichinella spiralis*),  
25 Toxocariasis (visceral larva migrans, caused by the invasion of organs by roundworm larvae, such as *Toxocara canis* and *Toxocara cati*), Pork tapeworm infection (*Taenia solium*), or Fish tapeworm infection (*Diphyllobothrium latum*).

Fungi tend to cause infections in people with a compromised immune system. Examples for fungal infections are Histoplasmosis (caused by *Histoplasma capsulatum*), Coccidioidomycosis  
30 (*Coccidioides immitis*), Blastomycosis (*Blastomyces dermatitidis*), Candidiasis (caused by strains of *Candida*, especially *Candida albicans*), or Sporotrichosis (*Sporothrix schenckii*).

Viral infections represent a very common type of infection. A virus is a small infectious particle that needs a living cell reproduce. Examples of viral infections are given in the following. Respiratory viral infections are, for example, common cold (caused by Picornaviruses [e.g. rhinoviruses], Influenza viruses or respiratory syncytial viruses), Influenza (caused by influenza A or influenza B virus), Herpesvirus Infections (herpes simplex, herpes zoster, Epstein-Barr virus, cytomegalovirus, herpesvirus 6, human herpesvirus 7, or herpesvirus 8 (cause of Kaposi's sarcoma in people with AIDS), central nervous system viral infections (e.g. Rabies, Creutzfeldt-Jakob disease (subacute spongiform encephalopathy), progressive multifocal leukoencephalopathy (rare manifestation of polyomavirus infection of the brain caused by the JC virus), Tropical spastic paraparesis (HTLV-I), Arbovirus infections (e.g. Arbovirus encephalitis, yellow fever, or dengue fever), Arenavirus Infections (e.g. Lymphocytic choriomeningitis), hemorrhagic fevers (e.g. Bolivian and Argentinean hemorrhagic fever and Lassa fever, Hantavirus infection, Ebola and Marburg viruses).

Human immunodeficiency virus (HIV) infection is an infection caused by HIV-1 or HIV-II virus. The infection results in progressive destruction of lymphocytes. This leads to acquired immunodeficiency syndrome (AIDS).

Examples of typical infections of people with an impaired immune system (opportunistic infections are including but are not limited to nocardiosis (caused by *Nocardia asteroides*), aspergillosis, mucormycosis, and cytomegalovirus infection.

Examples for sexually transmitted (venereal) diseases are syphilis (caused by *Treponema pallidum*), gonorrhea (*Neisseria gonorrhoeae*), chancroid (*Hemophilus ducreyi*), lymphogranuloma venereum (*Chlamydia trachomatis*), granuloma inguinale (*Calymmatobacterium granulomatis*), nongonococcal urethritis and chlamydial cervicitis (caused by *Chlamydia trachomatis*, *Ureaplasma urealyticum*, *Trichomonas vaginalis* or herpes simplex virus), trichomoniasis (*Trichomonas vaginalis*), genital candidiasis, genital herpes, genital warts (caused by papillomaviruses), or HIV infection.

The human PPAR-delta is highly expressed in the following antiinfective tissues: T-cells peripheral blood CD4+, T-cells peripheral blood CD4+, T-cells peripheral blood CD4+ D117 II virus infected, T-cells peripheral blood CD4+ D34 virus infected, monocytes, monocytes HIV-1 infected. The expression in the above mentioned tissues and in particular the differential expression between diseased tissue T-cells peripheral blood CD4+ D117 II virus infected and healthy tissue T-cells peripheral blood CD4+, between diseased tissue T-cells peripheral blood CD4+ D34 virus infected and healthy tissue T-cells peripheral blood CD4+, between diseased tissue monocytes HIV-1 infected and healthy tissue monocytes demonstrates that the human

PPAR-delta or mRNA can be utilized to diagnose of infective diseases. Additionally the activity of the human PPAR-delta can be modulated to treat infective diseases.

### *Applications*

5 The present invention provides for both prophylactic and therapeutic methods for cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases.

10 The regulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of PPARD. An agent that modulates activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of the polypeptide, a peptide, a peptidomimetic, or any small molecule. In one embodiment, the agent stimulates one or more of the biological activities of PPARD. Examples of such stimulatory agents include the active PPARD and nucleic acid molecules encoding a portion of PPARD. In another embodiment, the agent inhibits one or more of the biological activities of PPARD. Examples of such inhibitory  
15 agents include antisense nucleic acid molecules and antibodies. These regulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g. by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by unwanted expression or activity of PPARD or a protein in the PPARD signaling pathway. In one embodiment, the method involves  
20 administering an agent like any agent identified or being identifiable by a screening assay as described herein, or combination of such agents that modulate say upregulate or downregulate the expression or activity of PPARD or of any protein in the PPARD signaling pathway. In another embodiment, the method involves administering a regulator of PPARD as therapy to compensate for reduced or undesirably low expression or activity of PPARD or a protein in the PPARD  
25 signaling pathway.

Stimulation of activity or expression of PPARD is desirable in situations in which activity or expression is abnormally low and in which increased activity is likely to have a beneficial effect. Conversely, inhibition of activity or expression of PPARD is desirable in situations in which activity or expression of PPARD is abnormally high and in which decreasing its activity is likely to  
30 have a beneficial effect.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.



### Pharmaceutical Compositions

This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

5 The nucleic acid molecules, polypeptides, and antibodies (also referred to herein as "active compounds") of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like,  
10 compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The invention includes pharmaceutical compositions comprising a regulator of PPARD expression  
15 or activity (and/or a regulator of the activity or expression of a protein in the PPARD signaling pathway) as well as methods for preparing such compositions by combining one or more such regulators and a pharmaceutically acceptable carrier. Also within the invention are pharmaceutical compositions comprising a regulator identified using the screening assays of the invention packaged with instructions for use. For regulators that are antagonists of PPARD activity or which  
20 reduce PPARD expression, the instructions would specify use of the pharmaceutical composition for treatment of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases. For regulators that are agonists of PPARD activity or increase PPARD expression, the instructions would specify use  
25 of the pharmaceutical composition for treatment of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases.

An antagonist of PPARD may be produced using methods which are generally known in the art. In  
30 particular, purified PPARD may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind PPARD. Antibodies to PPARD may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain antibodies, Fab fragments,



and fragments produced by a Fab expression library. Neutralizing antibodies like those which inhibit dimer formation are especially preferred for therapeutic use.

In another embodiment of the invention, the polynucleotides encoding PPARD, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding PPARD may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding PPARD. Thus, complementary molecules or fragments may be used to modulate PPARD activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding PPARD.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors which will express nucleic acid sequence complementary to the polynucleotides of the gene encoding PPARD. These techniques are described, for example, in [Scott and Smith (1990) Science 249:386-390].

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition containing PPARD in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of PPARD, antibodies to PPARD, and mimetics, agonists, antagonists, or inhibitors of PPARD. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection,

saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EM<sup>TM</sup> (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a pharmaceutically acceptable polyol like glycerol, propylene glycol, liquid polyethylene glycol, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin. Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a polypeptide or antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the

active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.

- 5 Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or sterotes; a glidant such as  
10 colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

- 15 Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For  
20 transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

- 25 In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be  
30 apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharma-



ceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to  
5 physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the  
10 limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration. For pharmaceutical compositions which include an antagonist of PPARD activity, a compound which reduces expression of PPARD, or a compound which reduces  
15 expression or activity of a protein in the PPARD signaling pathway or any combination thereof, the instructions for administration will specify use of the composition for cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases. For pharmaceutical compositions which include an agonist of  
20 PPARD activity, a compound which increases expression of PPARD, or a compound which increases expression or activity of a protein in the PPARD signaling pathway or any combination thereof, the instructions for administration will specify use of the composition for cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases,  
25 urological diseases and reproduction diseases.

### Diagnostics

In another embodiment, antibodies which specifically bind PPARD may be used for the diagnosis of disorders characterized by the expression of PPARD, or in assays to monitor patients being treated with PPARD or agonists, antagonists, and inhibitors of PPARD. Antibodies useful for  
30 diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for PPARD include methods which utilize the antibody and a label to detect PPARD in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent joining with a



reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring PPARD, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of PPARD expression.

- 5 Normal or standard values for PPARD expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to PPARD under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, preferably by photometric means. Quantities of PPARD expressed in subject samples from biopsied tissues are compared with the standard values.
- 10 Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding PPARD may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of PPARD may be

15 correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of PPARD, and to monitor regulation of PPARD levels during therapeutic intervention.

Polynucleotide sequences encoding PPARD may be used for the diagnosis of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation,

20 hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases associated with expression of PPARD. The polynucleotide sequences encoding PPARD may be used in Southern, Northern, or dot-blot analysis, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and ELISA assays; and in microarrays utilizing fluids or tissues from patient biopsies to detect altered PPARD

25 expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding PPARD may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding PPARD may be labelled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes.

30 After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding PPARD in the sample indicates the presence of the associated disorder. Such assays may

also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases associated with expression of PPARD, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding PPARD, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with PPARD, or fragments thereof, and washed. Bound PPARD is then detected by methods well known in the art. Purified PPARD can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PPARD specifically compete with a test compound for binding PPARD. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PPARD.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with PPARD, or fragments thereof, and washed. Bound PPARD is then detected by methods well known in the art. Purified PPARD can also be coated directly onto plates for use in the afore-mentioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PPARD specifically compete with a test compound for binding PPARD. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PPARD.

## 5 Determination of a Therapeutically Effective Dose

The determination of a therapeutically effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient which increases or decreases PPARD activity relative to PPARD activity which occurs in the absence of the therapeutically effective dose. For any compound, the therapeutically effective dose can be  
10 estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

Therapeutic efficacy and toxicity, e.g.,  $ED_{50}$  (the dose therapeutically effective in 50% of the  
15 population) and  $LD_{50}$  (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio,  $LD_{50}/ED_{50}$ . Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for  
20 human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the  $ED_{50}$  with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient  
25 levels of the active ingredient or to maintain the desired effect. Factors which can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life  
30 and clearance rate of the particular formulation.

Normal dosage amounts can vary from 0.1 micrograms to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their



inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc. If the reagent is a single-chain antibody, polynucleotides encoding the antibody can be constructed and introduced into a cell either *ex vivo* or *in vivo* using well-established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun", and DEAE- or calcium phosphate-mediated transfection.

If the expression product is mRNA, the reagent is preferably an antisense oligonucleotide or a ribozyme. Polynucleotides which express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above. Preferably, a reagent reduces expression of PPARD gene or the activity of PPARD by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of expression of PPARD gene or the activity of PPARD can be assessed using methods well known in the art, such as hybridization of nucleotide probes to PPARD-specific mRNA, quantitative RT-PCR, immunologic detection of PPARD, or measurement of PPARD activity.

In any of the embodiments described above, any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects. Any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

Nucleic acid molecules of the invention are those nucleic acid molecules which are contained in a group of nucleic acid molecules consisting of (i) nucleic acid molecules encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, (ii) nucleic acid molecules comprising the sequence of SEQ ID NO: 1, (iii) nucleic acid molecules having the sequence of SEQ ID NO: 1, (iv) nucleic acid molecules the complementary strand of which hybridizes under stringent conditions to a nucleic acid molecule of (i), (ii), or (iii); and (v) nucleic acid molecules the sequence of which differs from the sequence of a nucleic acid molecule of (iii) due to the



degeneracy of the genetic code, wherein the polypeptide encoded by said nucleic acid molecule has PPARD activity.

Polypeptides of the invention are those polypeptides which are contained in a group of polypeptides consisting of (i) polypeptides having the sequence of SEQ ID NO: 2, (ii) polypeptides  
5 comprising the sequence of SEQ ID NO: 2, (iii) polypeptides encoded by nucleic acid molecules of the invention and (iv) polypeptides which show at least 99%, 98%, 95%, 90%, or 80% homology with a polypeptide of (i), (ii), or (iii), wherein said purified polypeptide has PPARD activity.

An object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections,  
10 cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising the steps of (i) contacting a test compound with a PPARD polypeptide, (ii) detect binding of said test compound to said PPARD polypeptide. E.g., compounds that bind to the PPARD polypeptide are identified potential therapeutic agents for  
15 such a disease.

Another object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hema-  
tological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological  
20 diseases and reproduction diseases in a mammal comprising the steps of (i) determining the activity of a PPARD polypeptide at a certain concentration of a test compound or in the absence of said test compound, (ii) determining the activity of said polypeptide at a different concentration of said test compound. E.g., compounds that lead to a difference in the activity of the PPARD polypeptide in (i) and (ii) are identified potential therapeutic agents for such a disease.

25 Another object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hema-  
tological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising the steps of (i) determining the  
30 activity of a PPARD polypeptide at a certain concentration of a test compound, (ii) determining the activity of a PPARD polypeptide at the presence of a compound known to be a regulator of a PPARD polypeptide. E.g., compounds that show similar effects on the activity of the PPARD polypeptide in (i) as compared to compounds used in (ii) are identified potential therapeutic agents for such a disease.

Other objects of the invention are methods of the above, wherein the step of contacting is in or at the surface of a cell.

Other objects of the invention are methods of the above, wherein the cell is in vitro.

5 Other objects of the invention are methods of the above, wherein the step of contacting is in a cell-free system.

Other objects of the invention are methods of the above, wherein the polypeptide is coupled to a detectable label.

Other objects of the invention are methods of the above, wherein the compound is coupled to a detectable label.

10 Other objects of the invention are methods of the above, wherein the test compound displaces a ligand which is first bound to the polypeptide.

Other objects of the invention are methods of the above, wherein the polypeptide is attached to a solid support.

15 Other objects of the invention are methods of the above, wherein the compound is attached to a solid support.

Another object of the invention is a method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological  
20 diseases and reproduction diseases in a mammal comprising the steps of (i) contacting a test compound with a PPARD polynucleotide, (ii) detect binding of said test compound to said PPARD polynucleotide. Compounds that, e.g., bind to the PPARD polynucleotide are potential therapeutic agents for the treatment of such diseases.

25 Another object of the invention is the method of the above, wherein the nucleic acid molecule is RNA.

Another object of the invention is a method of the above, wherein the contacting step is in or at the surface of a cell.

Another object of the invention is a method of the above, wherein the contacting step is in a cell-free system.

Another object of the invention is a method of the above, wherein the polynucleotide is coupled to a detectable label.

Another object of the invention is a method of the above, wherein the test compound is coupled to a detectable label.

- 5 Another object of the invention is a method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastro-  
enterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton  
diseases, neurological diseases, urological diseases and reproduction diseases in a mammal  
10 comprising the steps of (i) determining the amount of a PPARD polynucleotide in a sample taken  
from said mammal, (ii) determining the amount of PPARD polynucleotide in healthy and/or  
diseased mammal. A disease is diagnosed, e.g., if there is a substantial similarity in the amount of  
PPARD polynucleotide in said test mammal as compared to a diseased mammal.

Another object of the invention is a pharmaceutical composition for the treatment of a disease  
comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, derma-  
15 tological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic  
diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction  
diseases in a mammal comprising a therapeutic agent which binds to a PPARD polypeptide.

Another object of the invention is a pharmaceutical composition for the treatment of a disease  
comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, derma-  
20 tological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic  
diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction  
diseases in a mammal comprising a therapeutic agent which regulates the activity of a PPARD  
polypeptide.

Another object of the invention is a pharmaceutical composition for the treatment of a disease  
25 comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, derma-  
tological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic  
diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction  
diseases in a mammal comprising a therapeutic agent which regulates the activity of a PPARD  
polypeptide, wherein said therapeutic agent is (i) a small molecule, (ii) an RNA molecule, (iii) an  
30 antisense oligonucleotide, (iv) a polypeptide, (v) an antibody, or (vi) a ribozyme.

Another object of the invention is a pharmaceutical composition for the treatment of a disease  
comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, derma-

tological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising a PPARD polynucleotide.

5 Another object of the invention is a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising a PPARD polypeptide.

10 Another object of the invention is the use of regulators of a PPARD for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal.

15 Another object of the invention is a method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising the steps of (i) identifying a regulator of PPARD, (ii) determining whether said regulator ameliorates the symptoms of a disease  
20 comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal; and (iii) combining of said regulator with an acceptable pharmaceutical carrier.

25 Another object of the invention is the use of a regulator of PPARD for the regulation of PPARD activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases.

30 The uses, methods or compositions of the invention are useful for each single disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases.



The expression of human PPARD in hematological and metabolic related tissues (as described above) suggests a particular – but not limited to – utilization of PPARD for diagnosis and modulation of hematological diseases and metabolic diseases. Furthermore the above described expression suggest a – but not limited to – utilization of PPARD to cardiovascular diseases,  
5 infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases.

The examples below are provided to illustrate the subject invention. These examples are provided by way of illustration and are not included for the purpose of limiting the invention.

---

**Examples****Example 1: Search for homologous sequences in public sequence data bases**

The degree of homology can readily be calculated by known methods. Preferred methods to determine homology are designed to give the largest match between the sequences tested.

5 Methods to determine homology are codified in publicly available computer programs such as BestFit, BLASTP, BLASTN, and FASTA. The BLAST programs are publicly available from NCBI and other sources in the internet.

For PPARD the following hits to known sequences were identified by using the BLAST algorithm [Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ; Nucleic Acids Res 1997 Sep 1; 25(17): 3389-402] and the following set of parameters: matrix = BLOSUM62 and low complexity filter. The following databases were searched: NCBI (non-redundant database) and DERWENT patent database (Geneseq).

10

The following hits were found:

>gb|L07592.1|HUMPPARA Human peroxisome proliferator activated receptor mRNA, complete cds

15

Length = 3301, Score = 3517 bits (1829), Expect = 0.0, Identities = 1829/1829 (100%)

>dbj|AK122614.1| Homo sapiens cDNA FLJ16026 fis, clone DFNES2005690, highly similar to PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BETA

20

Length = 3725, Score = 2905 bits (1511), Expect = 0.0, Identities = 1511/1511 (100%)

>ref|NM\_177435.1| Homo sapiens peroxisome proliferative activated receptor, delta (PPARD), transcript variant 2, mRNA

25

Length = 1977, Score = 2271 bits (1181), Expect = 0.0, Identities = 1181/1181 (100%)

>gb|AY188501.1| Sus scrofa peroxisome proliferator-activated receptor delta (PPARd)mRNA, complete cds

Length = 1826, Score = 2046 bits (1064), Expect = 0.0, Identities = 1300/1418 (91%)

30 >gb|AF228697.1|AF228697 Sus scrofa peroxisome proliferator activated receptor beta (PPARbeta)mRNA, complete cds

Length = 1375, Score = 1931 bits (1004), Expect = 0.0, Identities = 1255/1376 (91%), Gaps = 2/1376 (0%)

- >dbj|AB033614.1| Oryctolagus cuniculus ppar-d/b mRNA for peroxisome proliferatoractivated receptor delta/beta, complete cds  
Length = 1326, Score = 1923 bits (1000), Expect = 0.0, Identities = 1216/1324 (91%)
- 5 >gb|AF229357.1|AF229357 Bos taurus peroxisome proliferator activated receptor beta (PPARbeta)mRNA, partial cds  
Length = 1354, Score = 1917 bits (997), Expect = 0.0, Identities = 1234/1353 (91%)
- 10 >gb|L28116.1|MUSPPARA Mus musculus peroxisome proliferator-activated receptor mRNA,complete cds  
Length = 1542, Score = 1750 bits (910), Expect = 0.0, Identities = 1249/1416 (88%), Gaps = 3/1416 (0%)
- 15 >gb|U40064.1|RNU40064 Rattus norvegicus PPAR delta protein (PPAR delta) mRNA, complete cds  
Length = 2054, Score = 1711 bits (890), Expect = 0.0, Identities = 1236/1404 (88%), Gaps = 4/1404 (0%)
- 20 >ref|NM\_013141.1| Rattus norvegicus peroxisome proliferator activated receptor delta(Ppard), mRNA  
Length = 2054, Score = 1711 bits (890), Expect = 0.0, Identities = 1236/1404 (88%), Gaps = 4/1404 (0%)
- 25 >gb|U75918.1|U75918 Rattus norvegicus peroxisome proliferator activated receptor deltamRNA, complete cds  
Length = 1975, Score = 1709 bits (889), Expect = 0.0, Identities = 1234/1404 (87%), Gaps = 3/1404 (0%)
- 30 >gb|U10375.1|MMU10375 Mus musculus peroxisome proliferator-activated receptor delta mRNA,complete cds  
Length = 1323, Score = 1698 bits (883), Expect = 0.0, Identities = 1180/1326 (88%), Gaps = 3/1326 (0%)

>emb|AJ306400.1|RNO306400 Rattus norvegicus mRNA for peroxisome proliferator-activated receptorbeta (PPARb gene)

Length = 1323, Score = 1663 bits (865), Expect = 0.0, Identities = 1174/1326 (88%), Gaps = 3/1326 (0%)

5

>dbj|AB099507.1| Homo sapiens PPARD mRNA for peroxisome proliferative activated receptor-delta isoform, partial cds

Length = 850, Score = 1575 bits (819), Expect = 0.0, Identities = 819/819 (100%)

10 >gb|AF163810.1|AF163810 Gallus gallus peroxisome proliferator-activated receptor beta(PPARbeta) mRNA, complete cds

Length = 1756, Score = 1217 bits (633), Expect = 0.0, Identities = 1148/1398 (82%), Gaps = 12/1398 (0%)

15 >emb|AL022721.1|HS109F14 Human DNA sequence from clone RP1-109F14 on chromosome 6p21.2-21.3 Contains the TEAD3 gene for TEA domain family member 3, the RPL10A gene for ribosomal protein RPL10a, the FANCE gene for Fanconi anemia, complementation group E, the gene for a novel putative ring finger protein, the PPARD gene for peroxisome proliferative activated receptor delta and six CpG islands, complete sequence

20 Length = 170245, Score = 1113 bits (579), Expect = 0.0, Identities = 601/607 (99%), Gaps = 3/607 (0%)

>gb|AF246303.1|AF246296S8 Homo sapiens peroxisome proliferative activated receptor delta(PPARD) gene, exon 9 and complete cds

25 Length = 2635, Score = 1113 bits (579), Expect = 0.0, Identities = 601/607 (99%), Gaps = 3/607 (0%)

>gb|AY442342.1| Homo sapiens peroxisome proliferative activated receptor, delta (PPARD) gene, complete cds

30 Length = 88955, Score = 1108 bits (576), Expect = 0.0, Identities = 600/607 (98%), Gaps = 3/607 (0%)

>gb|AF276755.1|AF276755 Mustela vison peroxisome proliferator activated receptor beta/deltamRNA, partial cds

35 Length = 690, Score = 977 bits (508), Expect = 0.0, Identities = 628/688 (91%)



>dbj|AK089913.1| Mus musculus melanocyte cDNA, RIKEN full-length enriched library, clone: G270140L11 product: peroxisome proliferator activator receptor delta, full insert sequence

Length = 1740, Score = 931 bits (484), Expect = 0.0, Identities = 656/742 (88%)

5

>emb|AJ243131.1|CNI243131 Crocodylus niloticus partial mRNA for peroxisome proliferator activated receptor beta (ppar gene)

Length = 912, Score = 887 bits (461), Expect = 0.0, Identities = 757/905 (83%)

10 >gb|AF246302.1|AF246296S7 Homo sapiens peroxisome proliferative activated receptor delta (PPARD) gene, exons 7 and 8

Length = 1071, Score = 869 bits (452), Expect = 0.0, Identities = 452/452 (100%)

>gb|AF486582.1| Mesocricetus auratus uterine peroxisome proliferator-activated receptor delta mRNA, partial cds

15

Length = 595, Score = 756 bits (393), Expect = 0.0, Identities = 527/594 (88%)

>emb|AJ416953.1|SSA416953 Salmo salar mRNA for peroxisomal proliferator-activated receptor beta1 (ppar beta1 gene)

20 Length = 1462, Score = 631 bits (328), Expect = e-177, Identities = 574/697 (82%)

>emb|AJ420922.1|MMU420922 Mus musculus partial PPARb/d gene for peroxisome proliferator activated receptor beta/delta, exons 4-8

Length = 8225, Score = 621 bits (323), Expect = e-174, Identities = 409/452 (90%)

25

>gb|AF342946.1|AF342946 Scophthalmus maximus peroxisome proliferator-activated receptor beta-like mRNA, partial sequence

Length = 995, Score = 565 bits (294), Expect = e-157, Identities = 763/995 (76%), Gaps = 1/995 (0%)

30 >gb|AF342937.1|AF342937 Danio rerio peroxisome proliferator-activated receptor beta 1 mRNA, partial cds

Length = 990, Score = 544 bits (283), Expect = e-151, Identities = 611/775 (78%)

>gb|AF342945.1|AF342945 Salmo salar peroxisome proliferator-activated receptor beta mRNA, partial cds

35

Length = 1012, Score = 539 bits (280), Expect = e-149, Identities = 550/685 (80%)

- >gb|U01665.1|U01665 Mus musculus BALB/c NUC1 mRNA, partial cds  
Length = 503, Score = 535 bits (278), Expect = e-148, Identities = 434/507 (85%), Gaps = 5/507 (0%)
- 5 >gb|AF013265.1|AF013265 Oryctolagus cuniculus peroxisome proliferator-activated receptor-beta (PPAR-beta) mRNA, partial cds  
Length = 337, Score = 490 bits (255), Expect = e-135, Identities = 305/330 (92%)
- 10 >gb|AY055372.1| Oryzias latipes peroxisome proliferator activated receptor isoform b(PPAR) mRNA, partial cds  
Length = 1011, Score = 473 bits (246), Expect = e-130, Identities = 732/975 (75%)
- >gb|AC140943.1| Gallus gallus chromosome UNK clone TAM32-50F18, complete sequence
- 15 Length = 142253, Score = 471 bits (245), Expect = e-129, Identities = 383/452 (84%)
- >gb|AF246299.1|AF246296S4 Homo sapiens peroxisome proliferative activated receptor delta (PPARD) gene, exon 4  
Length = 595, Score = 448 bits (233), Expect = e-122, Identities = 233/233 (100%)
- 20 >gb|AF342938.1|AF342938 Danio rerio peroxisome proliferator-activated receptor beta 2 mRNA, partial cds  
Length = 1107, Score = 379 bits (197), Expect = e-101, Identities = 594/790 (75%), Gaps = 3/790 (0%)
- 25 >gb|AF228696.1|AF228696 Sus scrofa peroxisome proliferator activated receptor alpha(PPARalpha) mRNA, partial cds  
Length = 1404, Score = 319 bits (166), Expect = 1e-83, Identities = 448/590 (75%)
- 30 >gb|AF246300.1|AF246296S5 Homo sapiens peroxisome proliferative activated receptor delta (PPARD) gene, exon 5  
Length = 542, Score = 306 bits (159), Expect = 2e-79, Identities = 159/159 (100%)

- >gb|AY055371.1| Pimephales promelas peroxisome proliferator activated receptor isoform b (PPAR) mRNA, partial cds  
Length = 701, Score = 300 bits (156), Expect = 8e-78, Identities = 373/479 (77%), Gaps = 3/479 (0%)
- 5
- >gb|AF350327.1|AF350327 Canis familiaris peroxisome proliferator activated receptor alpha mRNA, complete cds  
Length = 2032, Score = 292 bits (152), Expect = 2e-75, Identities = 571/778 (73%), Gaps = 3/778 (0%)
- 10
- >emb|AJ000222.1|CPAJ222 Cavia porcellus mRNA for peroxisome proliferator-activated receptor alpha  
Length = 2073, Score = 285 bits (148), Expect = 4e-73, Identities = 445/591 (75%), Gaps = 3/591 (0%)
- 15
- >emb|AJ006218.1|CPO6218 Cavia porcellus mRNA for peroxisome proliferator-activated receptor alpha  
Length = 1610, Score = 277 bits (144), Expect = 7e-71, Identities = 443/590 (75%), Gaps = 3/590 (0%)
- 20
- >gb|AF246301.1|AF246296S6 Homo sapiens peroxisome proliferative activated receptor delta (PPARD) gene, exon 6  
Length = 246, Score = 271 bits (141), Expect = 4e-69, Identities = 141/141 (100%)
- 25
- >gb|AF229356.1|AF229356 Bos taurus peroxisome proliferator activated receptor alpha (PPARalpha) mRNA, partial cds  
Length = 1411, Score = 248 bits (129), Expect = 4e-62, Identities = 435/588 (73%)
- 30
- >gb|AY166781.1| Oryctolagus cuniculus PPAR gamma 3 mRNA, complete cds  
Length = 1798, Score = 227 bits (118), Expect = 8e-56, Identities = 428/583 (73%)
- >gb|AY166780.1| Oryctolagus cuniculus PPAR gamma 1 mRNA, complete cds  
Length = 2123, Score = 227 bits (118), Expect = 8e-56, Identities = 428/583 (73%)

>gb|U84893.1|OCU84893 Oryctolagus cuniculus peroxisome proliferator activated  
receptorgamma-1 mRNA, complete cds

Length = 1759, Score = 217 bits (113), Expect = 6e-53, Identities = 415/566 (73%)

5 >dbj|AK081709.1| Mus musculus 16 days embryo head cDNA, RIKEN full-length enriched  
library, clone:C130070E08 product:peroxisome proliferator activated receptor alpha, full insert  
sequence

Length = 2519, Score = 208 bits (108), Expect = 5e-50, Identities = 190/231 (82%)

10 >dbj|AK035676.1| Mus musculus adult male urinary bladder cDNA, RIKEN full-length enriched  
library, clone:9530085L04 product:peroxisome proliferator activated receptor alpha, full insert  
sequence

Length = 3413, Score = 208 bits (108), Expect = 5e-50, Identities = 190/231 (82%).

## 15 **Example 2: Expression profiling**

Total cellular RNA was isolated from cells by one of two standard methods: 1) guanidine  
isothiocyanate/Cesium chloride density gradient centrifugation [Kellogg, (1990)] ; or with the Tri-  
Reagent protocol according to the manufacturer's specifications (Molecular Research Center, Inc.,  
Cincinnati, Ohio). Total RNA prepared by the Tri-reagent protocol was treated with DNase I to  
20 remove genomic DNA contamination.

For relative quantitation of the mRNA distribution of PPARD, total RNA from each cell or tissue  
source was first reverse transcribed. 85 µg of total RNA was reverse transcribed using 1 µmole  
random hexamer primers, 0.5 mM each of dATP, dCTP, dGTP and dTTP (Qiagen, Hilden,  
Germany), 3000 U RnaseQut (Invitrogen, Groningen, Netherlands) in a final volume of 680 µl.

25 The first strand synthesis buffer and Omniscript reverse transcriptase (2 u/µl) were from (Qiagen,  
Hilden, Germany). The reaction was incubated at 37°C for 90 minutes and cooled on ice. The  
volume was adjusted to 6800 µl with water, yielding a final concentration of 12.5 ng/µl of starting  
RNA.

30 For relative quantitation of the distribution of PPARD mRNA in cells and tissues the Applied  
Biosystems 7900 HT Sequence Detection system or Biorad iCycler was used according to the  
manufacturer's specifications and protocols. PCR reactions were set up to quantitate PPARD and the  
housekeeping genes HPRT (hypoxanthine phosphoribosyltransferase), GAPDH (glyceraldehyde-3-  
phosphate dehydrogenase), β-actin, and others. Forward and reverse primers and probes for  
PPARD were designed using the Perkin Elmer ABI Primer Express™ software and were



synthesized by TibMolBiol (Berlin, Germany). The PPARD forward primer sequence was: Primer1 (SEQ ID NO: 3). The PPARD reverse primer sequence was Primer2 (SEQ ID NO: 4). Probe1 (SEQ ID NO: 5), labelled with FAM (carboxyfluorescein succinimidyl ester) as the reporter dye and TAMRA (carboxytetramethylrhodamine) as the quencher, is used as a probe for PPARD. The following reagents were prepared in a total of 25 µl : 1x TaqMan buffer A, 5.5 mM MgCl<sub>2</sub>, 200 nM of dATP, dCTP, dGTP, and dUTP, 0.025 U/µl AmpliTaq Gold™, 0.01 U/µl AmpErase and Probe1 (SEQ ID NO: 5), PPARD forward and reverse primers each at 200 nM, 200 nM PPARD FAM/TAMRA-labelled probe, and 5 µl of template cDNA. Thermal cycling parameters were 2 min at 50°C, followed by 10 min at 95°C, followed by 40 cycles of melting at 95°C for 15 sec and annealing/extending at 60°C for 1 min.

#### *Calculation of corrected CT values*

The CT (threshold cycle) value is calculated as described in the "Quantitative determination of nucleic acids" section. The CF-value (factor for threshold cycle correction) is calculated as follows :

1. PCR reactions were set up to quantitate the housekeeping genes (HKG) for each cDNA sample.
2. CT<sub>HKG</sub>-values (threshold cycle for housekeeping gene) were calculated as described in the "Quantitative determination of nucleic acids" section.
3. CT<sub>HKG</sub>-mean values (CT mean value of all HKG tested on one cDNAs) of all HKG for each cDNA are calculated (n = number of HKG):  

$$CT_{HKG-n}\text{-mean value} = (CT_{HKG1}\text{-value} + CT_{HKG2}\text{-value} + \dots + CT_{HKG-n}\text{-value}) / n$$
4. CT<sub>panel</sub> mean value (CT mean value of all HKG in all tested cDNAs) =  

$$(CT_{HKG1}\text{-mean value} + CT_{HKG2}\text{-mean value} + \dots + CT_{HKG-y}\text{-mean value}) / y$$
(y = number of cDNAs)
5. CF<sub>cDNA-n</sub> (correction factor for cDNA n) = CT<sub>panel</sub>-mean value - CT<sub>HKG-n</sub>-mean value
6. CT<sub>cDNA-n</sub> (CT value of the tested gene for the cDNA n) + CF<sub>cDNA-n</sub> (correction factor for cDNA n) = CT<sub>cor-cDNA-n</sub> (corrected CT value for a gene on cDNA n)

*Calculation of relative expression*

Definition : highest  $CT_{cor-cDNA-n} \neq 40$  is defined as  $CT_{cor-cDNA} [high]$

Relative Expression =  $2^{(CT_{cor-cDNA}[high] - CT_{cor-cDNA-n})}$

*Tissues*

- 5 The expression of PPARD was investigated in the tissues listed in table 1.

*Expression profile*

The results of the the mRNA-quantification (expression profiling) is shown in Table 1.

Table 1: *Relative expression of PPARD in various human tissues*

T-cells peripheral blood CD4+	3641
T-cells peripheral blood CD4+	137
T-cells peripheral blood CD4+ D117 II virus infected	133
T-cells peripheral blood CD4+ D34 virus infected	145
monocytes	231
monocytes HIV-1 infected	292
fetal heart	93
heart	132
heart	82
heart	135
heart	1201
heart myocardial infarction	495
heart myocardial infarction	714
heart myocardial infarction	617
pericardium	468
heart atrium (right)	377
heart atrium (right)	207
heart atrium (left)	317
heart atrium (left)	309
heart ventricle (left)	10
heart ventricle (left)	221
heart ventricle (right)	41

heart ventricle (right)	242
heart apex	159
Purkinje fibers	193
interventricular septum	292
fetal aorta	30
aorta	68
aorta	26
aorta	14
arcus aorta	38
aorta valve	405
artery	20
coronary artery	12
coronary artery	64
coronary artery	30
pulmonary artery	25
carotid artery	33
mesenteric artery	182
arteria radialis	48
vein	24
pulmonic valve	33
vein (saphena magna)	59
(caval) vein	1
coronary artery endothel cells	526
coronary artery smooth muscle primary cells	146
aortic smooth muscle cells	549
pulmonary artery smooth muscle cells	290
aortic endothel cells	765
HUVEC cells	177
pulmonary artery endothel cells	153
iliac artery endothel cells	307
skin	449
adrenal gland	143
thyroid	739
thyroid tumor	657

pancreas	16
pancreas liver cirrhosis	86
esophagus	39
esophagus tumor	338
stomach	129
stomach tumor	695
colon	232
colon tumor	251
small intestine	132
ileum	288
ileum tumor	139
ileum chronic inflammation	0
rectum	320
rectum tumor	37
fetal liver	66
liver	96
liver	8
liver	9
liver liver cirrhosis	315
liver lupus disease	169
liver tumor	232
HEP G2 cells	838
leukocytes (peripheral blood)	229
Jurkat (T-cells)	111
Raji (B-cells)	93
bone marrow	30
erythrocytes	7
lymphnode	28
thymus	145
thrombocytes	26
bone marrow stromal cells	431
bone marrow CD71+ cells	9
bone marrow CD33+ cells	14
bone marrow CD34+ cells	28



bone marrow CD15+ cells	19
cord blood CD71+ cells	8
cord blood CD34+ cells	104
neutrophils cord blood	343
T-cells peripheral blood CD8+	1510
monocytes peripheral blood CD14+	163
B-cells peripheral blood CD19+	180
neutrophils peripheral blood	1663
spleen	152
spleen liver cirrhosis	288
skeletal muscle	147
cartilage	286
bone connective tissue	347
adipose	26
adipose	370
adipose	580
fetal adipose	505
adipose (subcutaneous) BMI 21.74	9
adipose (subcutaneous) BMI 35.04	3
brain	340
cerebellum	108
cerebral cortex	685
frontal lobe	1520
occipital lobe	714
parietal lobe	776
temporal lobe	695
substantia nigra	95
caudatum	724
corpus callosum	1176
nucleus accumbens	39
putamen	29
hippocampus	523
thalamus	256
posteroventral thalamus	58

dorsalmedial thalamus	58
hypothalamus	556
dorsal root ganglia	42
spinal cord	396
spinal cord (ventral horn)	111
spinal cord (dorsal horn)	31
glial tumor H4 cells	657
astrocytes	37
retina	49
fetal lung	194
fetal lung fibroblast IMR-90 cells	787
fetal lung fibroblast MRC-5 cells	422
lung	45
lung	43
lung	14
lung right upper lobe	284
lung right mid lobe	246
lung right lower lobe	410
lung lupus disease	82
lung tumor	175
lung COPD	35
trachea	115
primary bronchia	14
secondary bronchia	9
bronchial epithelial cells	3692
bronchial smooth muscle cells	1924
small airway epithelial cells	1193
cervix	40
testis	48
HeLa cells (cervix tumor)	59
placenta	803
uterus	140
uterus tumor	405
ovary	2721

ovary tumor	333
breast	399
breast tumor	315
mammary gland	249
prostate	198
prostate	474
prostate	402
prostate BPH	50
prostate tumor	31
bladder	149
bladder	350
bladder	530
ureter	237
penis	16
corpus cavernosum	56
<u>fetal kidney</u>	<u>729</u>
kidney	204
kidney	130
kidney	709
kidney tumor	744
renal epithelial cells	290
HEK 293 cells	422

### Example 3: Antisense Analysis

Knowledge of the correct, complete cDNA sequence coding for PPARD enables its use as a tool for antisense technology in the investigation of gene function. Oligonucleotides, cDNA or genomic fragments comprising the antisense strand of a polynucleotide coding for PPARD are used either in vitro or in vivo to inhibit translation of the mRNA. Such technology is now well known in the art, and antisense molecules can be designed at various locations along the nucleotide sequences. By treatment of cells or whole test animals with such antisense sequences, the gene of interest is effectively turned off. Frequently, the function of the gene is ascertained by observing behavior at the intracellular, cellular, tissue or organismal level (e.g., lethality, loss of differentiated function, changes in morphology, etc.).

In addition to using sequences constructed to interrupt transcription of a particular open reading frame, modifications of gene expression is obtained by designing antisense sequences to intron regions, promoter/enhancer elements, or even to trans-acting regulatory genes.

#### **Example 4: Expression of PPARD**

- 5 Expression of PPARD is accomplished by subcloning the cDNAs into appropriate expression vectors and transfecting the vectors into expression hosts such as, e.g., *E. coli*. In a particular case, the vector is engineered such that it contains a promoter for  $\beta$ -galactosidase, upstream of the cloning site, followed by sequence containing the amino-terminal Methionine and the subsequent seven residues of  $\beta$ -galactosidase. Immediately following these eight residues is an engineered  
10 bacteriophage promoter useful for artificial priming and transcription and for providing a number of unique endonuclease restriction sites for cloning.

- Induction of the isolated, transfected bacterial strain with Isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG) using standard methods produces a fusion protein corresponding to the first seven residues of  $\beta$ -galactosidase, about 15 residues of "linker", and the peptide encoded within the cDNA. Since  
15 cDNA clone inserts are generated by an essentially random process, there is probability of 33% that the included cDNA will lie in the correct reading frame for proper translation. If the cDNA is not in the proper reading frame, it is obtained by deletion or insertion of the appropriate number of bases using well known methods including in vitro mutagenesis, digestion with exonuclease III or mung bean nuclease, or the inclusion of an oligonucleotide linker of appropriate length.

- 20 The PPARD cDNA is shuttled into other vectors known to be useful for expression of proteins in specific hosts. Oligonucleotide primers containing cloning sites as well as a segment of DNA (about 25 bases) sufficient to hybridize to stretches at both ends of the target cDNA is synthesized chemically by standard methods. These primers are then used to amplify the desired gene segment by PCR. The resulting gene segment is digested with appropriate restriction enzymes under  
25 standard conditions and isolated by gel electrophoresis. Alternately, similar gene segments are produced by digestion of the cDNA with appropriate restriction enzymes. Using appropriate primers, segments of coding sequence from more than one gene are ligated together and cloned in appropriate vectors. It is possible to optimize expression by construction of such chimeric sequences.

- 30 Suitable expression hosts for such chimeric molecules include, but are not limited to, mammalian cells such as Chinese Hamster Ovary (CHO) and human 293 cells., insect cells such as Sf9 cells, yeast cells such as *Saccharomyces cerevisiae* and bacterial cells such as *E. coli*. For each of these cell systems, a useful expression vector also includes an origin of replication to allow propagation



in bacteria, and a selectable marker such as the  $\beta$ -lactamase antibiotic resistance gene to allow plasmid selection in bacteria. In addition, the vector may include a second selectable marker such as the neomycin phosphotransferase gene to allow selection in transfected eukaryotic host cells. Vectors for use in eukaryotic expression hosts require RNA processing elements such as 3' polyadenylation sequences if such are not part of the cDNA of interest.

Additionally, the vector contains promoters or enhancers which increase gene expression. Such promoters are host specific and include MMTV, SV40, and metallothionine promoters for CHO cells; trp, lac, tac and T7 promoters for bacterial hosts; and alpha factor, alcohol oxidase and PGH promoters for yeast. Transcription enhancers, such as the rous sarcoma virus enhancer, are used in mammalian host cells. Once homogeneous cultures of recombinant cells are obtained through standard culture methods, large quantities of recombinantly produced PPARD are recovered from the conditioned medium and analyzed using chromatographic methods known in the art. For example, PPARD can be cloned into the expression vector pcDNA3, as exemplified herein. This product can be used to transform, for example, HEK293 or COS by methodology standard in the art. Specifically, for example, using Lipofectamine (Gibco BRL catalog no. 18324-020) mediated gene transfer.

---

#### **Example 5: Isolation of Recombinant PPARD**

PPARD is expressed as a chimeric protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals [Appa Rao, 1997] and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Washington). The inclusion of a cleavable linker sequence such as Factor Xa or enterokinase (Invitrogen, Groningen, The Netherlands) between the purification domain and the PPARD sequence is useful to facilitate expression of PPARD.

#### **Example 6: Production of PPARD Specific Antibodies**

Two approaches are utilized to raise antibodies to PPARD, and each approach is useful for generating either polyclonal or monoclonal antibodies. In one approach, denatured protein from reverse phase HPLC separation is obtained in quantities up to 75 mg. This denatured protein is used to immunize mice or rabbits using standard protocols; about 100  $\mu$ g are adequate for immunization of a mouse, while up to 1 mg might be used to immunize a rabbit. For identifying mouse hybridomas, the denatured protein is radioiodinated and used to screen potential murine B-cell hybridomas for those which produce antibody. This procedure requires only small quantities of protein, such that 20 mg is sufficient for labeling and screening of several thousand clones.

In the second approach, the amino acid sequence of an appropriate PPARD domain, as deduced from translation of the cDNA, is analyzed to determine regions of high antigenicity. Oligopeptides comprising appropriate hydrophilic regions are synthesized and used in suitable immunization protocols to raise antibodies. The optimal amino acid sequences for immunization are usually at the C-terminus, the N-terminus and those intervening, hydrophilic regions of the polypeptide which are likely to be exposed to the external environment when the protein is in its natural conformation.

Typically, selected peptides, about 15 residues in length, are synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry and coupled to keyhole limpet hemocyanin (KLH; Sigma, St. Louis, MO) by reaction with M-maleimidobenzoyl-N-hydroxy-succinimide ester, MBS. If necessary, a cysteine is introduced at the N-terminus of the peptide to permit coupling to KLH. Rabbits are immunized with the peptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity by binding the peptide to plastic, blocking with 1% bovine serum albumin, reacting with antisera, washing and reacting with labeled (radioactive or fluorescent), affinity purified, specific goat anti-rabbit IgG.

Hybridomas are prepared and screened using standard techniques. Hybridomas of interest are detected by screening with labeled PPARD to identify those fusions producing the monoclonal antibody with the desired specificity. In a typical protocol, wells of plates (FAST; Becton-Dickinson, Palo Alto, CA) are coated during incubation with affinity purified, specific rabbit anti-mouse (or suitable antispecies 1 g) antibodies at 10 mg/ml. The coated wells are blocked with 1% bovine serum albumin, (BSA), washed and incubated with supernatants from hybridomas. After washing the wells are incubated with labeled PPARD at 1 mg/ml. Supernatants with specific antibodies bind more labeled PPARD than is detectable in the background. Then clones producing specific antibodies are expanded and subjected to two cycles of cloning at limiting dilution. Cloned hybridomas are injected into pristane-treated mice to produce ascites, and monoclonal antibody is purified from mouse ascitic fluid by affinity chromatography on Protein A. Monoclonal antibodies with affinities of at least

$10^8 \text{ M}^{-1}$ , preferably  $10^9$  to  $10^{10} \text{ M}^{-1}$  or stronger, are typically made by standard procedures.

#### **Example 7: Diagnostic Test Using PPARD Specific Antibodies**

Particular PPARD antibodies are useful for investigating signal transduction and the diagnosis of infectious or hereditary conditions which are characterized by differences in the amount or distribution of PPARD or downstream products of an active signaling cascade.

Diagnostic tests for PPARD include methods utilizing antibody and a label to detect PPARD in human body fluids, membranes, cells, tissues or extracts of such. The polypeptides and antibodies of the present invention are used with or without modification. Frequently, the polypeptides and antibodies are labeled by joining them, either covalently or noncovalently, with a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and have been reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents, chromogenic agents, magnetic particles and the like.

A variety of protocols for measuring soluble or membrane-bound PPARD, using either polyclonal or monoclonal antibodies specific for the protein, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PPARD is preferred, but a competitive binding assay may be employed.

#### 15 **Example 8: Purification of Native PPARD Using Specific Antibodies**

Native or recombinant PPARD is purified by immunoaffinity chromatography using antibodies specific for PPARD. In general, an immunoaffinity column is constructed by covalently coupling the anti-TRH antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated Sepharose (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such immunoaffinity columns are utilized in the purification of PPARD by preparing a fraction from cells containing PPARD in a soluble form. This preparation is derived by solubilization of whole cells or of a subcellular fraction obtained via differential centrifugation (with or without addition of detergent) or by other methods well known in the art. Alternatively, soluble PPARD containing a signal sequence is secreted in useful quantity into the medium in which the cells are grown.

A soluble PPARD-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PPARD (e.g., high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/protein binding (e.g., a buffer of pH 2-3 or a high concentration of a chaotrope such as urea or thiocyanate ion), and PPARD is collected.

#### **Example 9: Drug Screening**

This invention is particularly useful for screening therapeutic compounds by using PPARD or binding fragments thereof in any of a variety of drug screening techniques. As PPARD is a Nuclear Receptor any of the methods commonly used in the art may potentially be used to identify PPARD ligands. For example, the activity of a Nuclear Receptor such as PPARD can be measured using any of a variety of appropriate functional assays in which activation of the receptor results in an observable change in the level of a reportergene which is transcriptionally activated by the Nuclear Receptor. Alternatively, the polypeptide or fragment employed in such a test is either free in solution, affixed to a solid support, borne on a cell surface or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, are used for standard binding assays.

Measured, for example, is the formation of complexes between PPARD and the agent being tested. Alternatively, one examines the diminution in complex formation between PPARD and a ligand caused by the agent being tested.

Thus, the present invention provides methods of screening for drug candidates, drugs, or any other agents which affect signal transduction. These methods, well known in the art, comprise contacting such an agent with PPARD polypeptide or a fragment thereof and assaying (i) for the presence of a complex between the agent and PPARD polypeptide or fragment, or (ii) for the presence of a complex between PPARD polypeptide or fragment and the cell. In such competitive binding assays, the PPARD polypeptide or fragment is typically labeled. After suitable incubation, free PPARD polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to PPARD or to interfere with the PPARD-agent complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to PPARD polypeptides. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other



surface. The peptide test compounds are reacted with PPARD polypeptide and washed. Bound PPARD polypeptide is then detected by methods well known in the art. Purified PPARD are also coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies are used to capture the peptide and immobilize it on the solid support.

- 5 This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding PPARD specifically compete with a test compound for binding to PPARD polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic determinants with PPARD.

#### **Example 10: Rational Drug Design**

- 10 The goal of rational drug design is to produce structural analogs of biologically active polypeptides of interest or of small molecules with which they interact, agonists, antagonists, or inhibitors. Any of these examples are used to fashion drugs which are more active or stable forms of the polypeptide or which enhance or interfere with the function of a polypeptide in vivo.

- In one approach, the three-dimensional structure of a protein of interest, or of a protein-inhibitor  
15 complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a  
combination of the two approaches. Both the shape and charges of the polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of a polypeptide is gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design  
20 efficient inhibitors. Useful examples of rational drug design include molecules which have improved activity or stability or which act as inhibitors, agonists, or antagonists of native peptides.

- It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design is based. It is possible to bypass protein crystallography  
25 altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids is expected to be an analog of the original receptor. The anti-id is then used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides then act as the pharmacore.

- 30 By virtue of the present invention, sufficient amount of polypeptide are made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the PPARD amino

acid sequence provided herein provides guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

**Example 11: Identification of Other Members of the Signal Transduction Complex**

The inventive purified PPARD is a research tool for identification, characterization and purification of other signal transduction pathway proteins. Radioactive labels are incorporated into a selected PPARD domain by various methods known in the art and used in vitro to capture interacting molecules. A preferred method involves labeling the primary amino groups in PPARD with  $^{125}\text{I}$  Bolton-Hunter reagent. This reagent has been used to label various molecules without concomitant loss of biological activity.

Labeled PPARD is useful as a reagent for the purification of molecules with which it interacts. In one embodiment of affinity purification, membrane-bound PPARD is covalently coupled to a chromatography column. Cell-free extract derived from synovial cells or putative target cells is passed over the column, and molecules with appropriate affinity bind to PPARD. PPARD-complex is recovered from the column, and the PPARD-binding ligand disassociated and subjected to N-terminal protein sequencing. The amino acid sequence information is then used to identify the captured molecule or to design degenerate oligonucleotide probes for cloning the relevant gene from an appropriate cDNA library.

In an alternate method, antibodies are raised against PPARD, specifically monoclonal antibodies. The monoclonal antibodies are screened to identify those which inhibit the binding of labeled PPARD. These monoclonal antibodies are then used therapeutically.

**Example 12: Use and Administration of Antibodies, Inhibitors, or Antagonists**

Antibodies, inhibitors, or antagonists of PPARD or other treatments and compounds that are limiters of signal transduction (LSTs), provide different effects when administered therapeutically. LSTs are formulated in a nontoxic, inert, pharmaceutically acceptable aqueous carrier medium preferably at a pH of about 5 to 8, more preferably 6 to 8, although pH may vary according to the characteristics of the antibody, inhibitor, or antagonist being formulated and the condition to be treated. Characteristics of LSTs include solubility of the molecule, its half-life and antigenicity/-immunogenicity. These and other characteristics aid in defining an effective carrier. Native human proteins are preferred as LSTs, but organic or synthetic molecules resulting from drug screens are equally effective in particular situations.

LSTs are delivered by known routes of administration including but not limited to topical creams and gels; transmucosal spray and aerosol; transdermal patch and bandage; injectable, intravenous

and lavage formulations; and orally administered liquids and pills particularly formulated to resist stomach acid and enzymes. The particular formulation, exact dosage, and route of administration is determined by the attending physician and varies according to each specific situation.

Such determinations are made by considering multiple variables such as the condition to be treated, the LST to be administered, and the pharmacokinetic profile of a particular LST. Additional factors which are taken into account include severity of the disease state, patient's age, weight, gender and diet, time and frequency of LST administration, possible combination with other drugs, reaction sensitivities, and tolerance/response to therapy. Long acting LST formulations might be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular LST.

Normal dosage amounts vary from 0.1 to  $10^5$   $\mu$ g, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212. Those skilled in the art employ different formulations for different LSTs. Administration to cells such as nerve cells necessitates delivery in a manner different from that to other cells such as vascular endothelial cells.

It is contemplated that abnormal signal transduction, trauma, or diseases which trigger PPARD activity are treatable with LSTs. These conditions or diseases are specifically diagnosed by the tests discussed above, and such testing should be performed in suspected cases of viral, bacterial or fungal infections, allergic responses, mechanical injury associated with trauma, hereditary diseases, lymphoma or carcinoma, or other conditions which activate the genes of lymphoid or neuronal tissues.

### **Example 13: Production of Non-human Transgenic Animals**

Animal model systems which elucidate the physiological and behavioral roles of the PPARD are produced by creating nonhuman transgenic animals in which the activity of the PPARD is either increased or decreased, or the amino acid sequence of the expressed PPARD is altered, by a variety of techniques. Examples of these techniques include, but are not limited to: 1) Insertion of normal or mutant versions of DNA encoding a PPARD, by microinjection, electroporation, retroviral transfection or other means well known to those skilled in the art, into appropriately fertilized embryos in order to produce a transgenic animal or 2) homologous recombination of mutant or normal, human or animal versions of these genes with the native gene locus in transgenic animals to alter the regulation of expression or the structure of these PPARD sequences. The technique of homologous recombination is well known in the art. It replaces the native gene

with the inserted gene and hence is useful for producing an animal that cannot express native PPARDs but does express, for example, an inserted mutant PPARD, which has replaced the native PPARD in the animal's genome by recombination, resulting in underexpression of the transporter. Microinjection adds genes to the genome, but does not remove them, and the technique is useful  
5 for producing an animal which expresses its own and added PPARD, resulting in overexpression of the PPARD.

One means available for producing a transgenic animal, with a mouse as an example, is as follows: Female mice are mated, and the resulting fertilized eggs are dissected out of their oviducts. The eggs are stored in an appropriate medium such as cesiumchloride M2 medium. DNA or cDNA  
10 encoding PPARD is purified from a vector by methods well known to the one skilled in the art. Inducible promoters may be fused with the coding region of the DNA to provide an experimental means to regulate expression of the transgene. Alternatively or in addition, tissue specific regulatory elements may be fused with the coding region to permit tissue-specific expression of the transgene. The DNA, in an appropriately buffered solution, is put into a microinjection needle  
15 (which may be made from capillary tubing using a piper puller) and the egg to be injected is put in a depression slide. The needle is inserted into the pronucleus of the egg, and the DNA solution is injected. The injected egg is then transferred into the oviduct of a pseudopregnant mouse which is a mouse stimulated by the appropriate hormones in order to maintain false pregnancy, where it proceeds to the uterus, implants, and develops to term. As noted above, microinjection is not the  
20 only method for inserting DNA into the egg but is used here only for exemplary purposes.

### References

- U.S. 4,522,811  
U.S. 5,283,317  
U.S. 5,565,332  
25 U.S. 6,689,574  
WO 93/03151  
WO 94/13804  
WO 02/064632  
Altschul SF et al., Nucleic Acids Res 1997 Sep 1; 25(17): 3389-402  
30 Appa Rao et al., 1997, Protein Expr Purif Nov, 11(2): 201-8  
Barnes, 2000, Chest, 117:10S14S  
Berger et al., 1992, J Steroid Biochem Mol Biol. 41 (3-8): 733-738  
Botstein et al., 1980, Am J Hum Genet. 32: 314-31  
Bourguet et al., 2000, Trends Pharmacol. Sci. 21: 381-388



- Charles et al., 2000, *J Appl Toxicol.* 20, 6: 449-454
- Colbere-Garapin *et al.*, 1981, *J. Mol. Biol.* 150, 1-14
- Engelhard *et al.*, 1994, *Proc. Nat. Acad. Sci.* 91, 3224-3227
- Gergen and Weiss , 1992, *Am Rev Respir Dis* 146:823-824
- 5 Gibson et al., 1996, *Genome Research* 6: 995-1001
- Gutendorf, B. and Westendorf, J.(2001) *Toxicology* 166: 79-89
- Haseloff *et al.*, 1988 , *Nature* 334, 585-591
- Heid et al., 1996, *Genome Research* 6: 986-994
- Holland et al., 1991, *PNAS* 88: 7276-7280
- 10 Iwabuchi *et al.*, 1993, *Oncogene* 8, 1693-1696
- Jeffreys et al., 1985, *Nature* 316: 76-9
- Johnson *et al.*, 1989, *Endoc. Rev.* 10, 317-331
- Kellogg et al., 1990, *Anal. Biochem.* 189:202-208
- Kersten et al. (2000), *Nature* 405: 421-424
- 15 Lam , 1997, *Anticancer Drug Res.* 12(3):145-67
- Lee et al., 1998, *Mol Endocrinol.* 12(8): 1184-1192
- 
- Livak et al., 1995 , *PCR Methods and Applications* 357-362
- 
- Logan, Shenk, 1984, *Proc. Natl. Acad. Sci.* 81, 3655-3659
- Lowy *et al.*, 1980, *Cell* 22, 817-23
- 20 Maddox *et al.*, 1983, *J. Exp. Med.* 158, 1211-1216
- McConnell *et al.* , 1992 , *Science* 257, 1906-1912
- Nicholls *et al.*, 1993, *J. Immunol. Meth.* 165, 81-91
- Nichols et al., 1998, *Anal Biochem.* 257: 112-119
- Olefsky & Jerrold M., (2001) *J Biol Chem*, Vol. 276, No.40 Issue 5: 36863-36864
- 25 Piatak et al., 1993, *BioTechniques* 14:70-81
- Piatak et al., 1993, *Science* 259:1749-1754
- Porath *et al.*, 1992, *Prot. Exp. Purif.* 3, 263-281
- Roberge *et al.*, 1995, *Science* 269, 202-204
- Robinson-Rechavi et al., (2003) *J Struct Funct Genomics.* 3(1-4):177-84
- 30 Rosen J. et al., 2003, *Drug Discovery & Developement* Vol 6 No 2: 224-230
- Schmidt et al. (1992), *Molec. Endocr.* 6: 1634-1641
- Sjolander, Urbaniczky, 1991, *Anal. Chem.* 63, 2338-2345
- Szabo *et al.*, 1995, *Curr. Opin. Struct. Biol.* 5, 699-705
- Thomas, 1980, *Proc. Nat. Acad. Sci.*, 77:5201-5205
- 35 Uhlmann *et al.*, 1987, *Tetrahedron. Lett.* 215, 3539-3542
- Weber et al., 1990, *Genomics* 7: 524-30
-

Wigler *et al.*, 1977, *Cell* 11, 223-32

Wigler *et al.*, 1980, *Proc. Natl. Acad. Sci.* 77, 3567-70

---

---

---

---



Claims

1. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising the steps of
  - i) contacting a test compound with a PPARD polypeptide,
  - ii) detect binding of said test compound to said PPARD polypeptide.
2. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising the steps of
  - i) determining the activity of a PPARD polypeptide at a certain concentration of a test compound or in the absence of said test compound,
  - ii) determining the activity of said polypeptide at a different concentration of said test compound.
3. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising the steps of
  - i) determining the activity of a PPARD polypeptide at a certain concentration of a test compound,
  - ii) determining the activity of a PPARD polypeptide at the presence of a compound known to be a regulator of a PPARD polypeptide.
4. The method of any of claims 1 to 3, wherein the step of contacting is in or at the surface of a cell.
5. The method of any of claims 1 to 3, wherein the cell is in vitro.



6. The method of any of claims 1 to 3, wherein the step of contacting is in a cell-free system.
7. The method of any of claims 1 to 3, wherein the polypeptide is coupled to a detectable label.
8. The method of any of claims 1 to 3, wherein the compound is coupled to a detectable label.
- 5 9. The method of any of claims 1 to 3, wherein the test compound displaces a ligand which is first bound to the polypeptide.
10. The method of any of claims 1 to 3, wherein the polypeptide is attached to a solid support.
11. The method of any of claims 1 to 3, wherein the compound is attached to a solid support.
- 10 12. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising the steps of
  - i) contacting a test compound with a PPARD polynucleotide,
  - 15 ii) detect binding of said test compound to said PPARD polynucleotide.
13. The method of claim 12 wherein the nucleic acid molecule is RNA.
14. The method of claim 12 wherein the contacting step is in or at the surface of a cell.
15. The method of claim 12 wherein the contacting step is in a cell-free system.
16. The method of claim 12 wherein polynucleotide is coupled to a detectable label.
- 20 17. The method of claim 12 wherein the test compound is coupled to a detectable label.
- 25 18. A method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising the steps of
  - i) determining the amount of a PPARD polynucleotide in a sample taken from said mammal,

- ii) determining the amount of PPARD polynucleotide in healthy and/or diseased mammals.
19. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising a therapeutic agent which binds to a PPARD polypeptide.
20. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising a therapeutic agent which regulates the activity of a PPARD polypeptide.
21. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising a therapeutic agent which regulates the activity of a PPARD polypeptide, wherein said therapeutic agent is
- i) a small molecule,
  - ii) an RNA molecule,
  - iii) an antisense oligonucleotide,
  - iv) a polypeptide,
  - v) an antibody, or
  - vi) a ribozyme.
22. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising a PPARD polynucleotide.

23. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising a PPARD polypeptide.
24. Use of regulators of a PPARD for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal.
25. Method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal comprising the steps of
- i) identifying a regulator of PPARD,
  - ii) determining whether said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases in a mammal; and
  - iii) combining of said regulator with an acceptable pharmaceutical carrier.
26. Use of a regulator of PPARD for the regulation of PPARD activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases.

24. März 2004

- 106 -

**Diagnostics and Therapeutics for Diseases Associated with Peroxisome Proliferator  
Activated Receptor Delta (PPARD)**

Abstract of Disclosure

The invention provides a human PPARD which is associated with the cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, cancer, dermatological diseases, gastroenterological diseases, inflammation, hematological diseases, metabolic diseases, muscle-skeleton diseases, neurological diseases, urological diseases and reproduction diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PPARD as well as pharmaceutical compositions comprising such compounds.

---





24. März 2004

**Fig. 1****SEQ ID NO: 1**

GAATTCTGCGGAGCCTGCGGGACGGCGGGCGGGTTGGCCCGTAGGCAGC  
CGGGACAGTGTTGTACAGTGTTTTGGGCATGCACGTGATACTCACACA  
GTGGCTTCTGCTCACCAACAGATGAAGACAGATGCACCAACGAGGGTC  
TGGAATGGTCTGGAGTGGTCTGGAAAGCAGGGTCAGATACCCCTGGAA  
AACTGAAGCCCGTGGAGCAATGATCTCTACAGGACTGCTTCAAGGCTG  
ATGGGAACCACCCTGTAGAGGTCCATCTGCGTTCAGACCCAGACGATG  
CCAGAGCTATGACTGGGCCTGCAGGTGTGGCGCCGAGGGGAGATCAGC  
CATGGAGCAGCCACAGGAGGAAGCCCCTGAGGTCCGGGAAGAGGAGGA  
GAAAGAGGAAGTGGCAGAGGCAGAAGGAGCCCCAGAGCTCAATGGGGG  
ACCACAGCATGCACTTCCTTCCAGCAGCTACACAGACCTCTCCCGGAG  
CTCCTCGCCACCCTCACTGCTGGACCAACTGCAGATGGGCTGTGACGG  
GGCCTCATGCGGCAGCCTCAACATGGAGTGCCGGGTGTGCGGGGACAA  
GGCATCGGGCTTCCACTACGGTGTTTCATGCATGTGAGGGGTGCAAGGG  
CTTCTTCCGTCGTACGATCCGCATGAAGCTGGAGTACGAGAAGTGTGA  
GCGCAGCTGCAAGATTCAGAAGAAGAACCGCAACAAGTGCCAGTACTG  
CCGCTTCCAGAAGTGCCCTGGCACTGGGCATGTCACACAACGCTATCCG  
TTTTGGTCGGATGCCGGAGGCTGAGAAGAGGAAGCTGGTGGCAGGGCT  
GACTGCAAACGAGGGGAGCCAGTACAACCCACAGGTGGCCGACCTGAA  
GGCCTTCTCCAAGCACATCTACAATGCCTACCTGAAAAACTTCAACAT  
GACCAAAAAGAAGGCCCGCAGCATCCTCACCGGCAAAGCCAGCCACAC  
GGCGCCCTTTGTGATCCACGACATCGAGACATTGTGGCAGGCAGAGAA  
GGGGCTGGTGTGGAAGCAGTTGGTGAATGGCCTGCCTCCCTACAAGGA  
GATCAGCGTGCACGTCTTCTACCGCTGCCAGTGCACCACAGTGGAGAC  
CGTGCGGGAGCTCACTGAGTTCGCCAAGAGCATCCCCAGCTTCAGCAG  
CCTCTTCCTCAACGACCAGGTTACCCTTCTCAAGTATGGCGTGCACGA  
GGCCATCTTCGCCATGCTGGCCTCTATCGTCAACAAGGACGGGGCTGCT  
GGTAGCCAACGGCAGTGGCTTTGTACCCGTGAGTTCCTGCGCAGCCT  
CCGCAAACCCTTCAGTGATATCATTGAGCCTAAGTTTGAATTTGCTGT

**Fig. 1** (continued)

CAAGTTCAACGCCCTGGAACCTTGATGACAGTGACCTGGCCCTATTCAT  
TGCGGCCATCATTCCTGTGTGGAGACCGGCCAGGCCTCATGAACGTTCC  
ACGGGTGGAGGCTATCCAGGACACCATCCTGCGTGCCCTCGAATTCCA  
CCTGCAGGCCAACCACCCTGATGCCCAGTACCTCTTCCCCAAGCTGCT  
GCAGAAGATGGCTGACCTGCGGCAACTGGTCACCGAGCACGCCCAGAT  
GATGCAGCGGATCAAGAAGACCGAAACCGAGACCTCGCTGCACCCTCT  
GCTCCAGGAGATCTACAAGGACATGTACTAACGGCGGCACCCAGGCCT  
CCCTGCAGACTCCAATGGGGCCAGCACTGGAGGGGGCCACCCACATGA  
CTTTTCCATTGACCAGCTCTCTTCCTGTCTTTGTTGTCTCCCTCTTTC  
TCAGTTCCTCTTTCTTTTCTAATTCCTGTTGCTCTGTTTCTTCCTTTC  
TGTAGGTTTCTCTCTTCCCTTCTCCCTTCTCCCTTGCCCTCCCTTTCT  
CTCTCCTATCCCCACGTCTGTCCTCCTTTCTTATTCTGTGAGATGTTT  
TGTATTATTTACCCAGCAGCATAGAAGAGGAGCTCTGCTTTTGCACAC  
CTTTTCCCCAGGAGCAGAAGAGAGTGGGCCTGCCCTCTGCCCCATCAT  
TGCACCTGCAGGCTTAGGTCCTCACTTCTGTCTCCTGTCTTCAGAGCA  
AAAGACTTGAGCCATCCAAAGAAACACTAAGCTCTCTGGGCCTGGGT  
CCAGGGAAGGCTAAGCATGGCCTGGACTGACTGCAGCCCCCTATAGTC  
ATGGGGTCCCTGCTGCAAAGGACAGTGGCAGACCCCGGCAGTAGAGCC  
GAGATGCCTCCCCAAGACTGTCATTGCCCTCCGATCGTGAGGCCACC  
CACTGACCCAATGATCCTCTCCAGCAGCACACCTCAGCCCCACTGACA  
CCCAGTGTCTTCCATCTTCACACTGGTTTGCCAGGCCAATGTTGCTG  
ATGGCCCCCTCCAGCACACACACATAAGCACTGAAATCACTTTACCTGC  
AGGCACCATGCACCTCCCTTCCCTCCCTGAGGCAGGTGAGAACCAGAG  
GAGAGGGGGCCTGCAGGTGAGCAGGCAGGGCTGGGCCAGGTCTCCGGGG  
AGGCAGGGGGTCCTGCAGGTCTTGGTGGGTGAGCCCAGCACCTCGCCCA  
GTGGGAGCTTCCCGGGATAAACTGAGCCTGTTTCATTCTGATGTCCATT  
TGTCCCAATAGCTCTACTGCCCTCCCCTTCCCCTTTACTCAGCCCAGC  
TGGCCACCTAGAAGTCTCCCTGCACAGCCTCTAGTGTCCGGGGACCTT  
GTGGGACCAGTCCCACACCGCTGGTCCCTGCCCTCCCCTGCTCCCAGG

**Fig. 1** (continued)

TTGAGGTGCGCTCACCTCAGAGCAGGGCCAAAGCACAGCTGGGCATGC  
CATGTCTGAGCGGCGCAGAGCCCTCCAGGCCTGCAGGGGCAAGGGGCT  
GGCTGGAGTCTCAGAGCACAGAGGTAGGAGAACTGGGGTTCAAGCCCA  
GGCTTCCTGGGTCCTGCCTGGTCCTCCCTCCCAAGGAGCCATTCTATG  
TGACTCTGGGTGGAAGTGCCCAGCCCCCTGCCTGACGGNNNNNNNGATC  
ACTCTCTGCTGGCAGGATTCTTCCCGCTCCCCACCTACCCAGCTGATG  
GGGGTTGGGGTGCTTCTTTCAGCCAAGGCTATGAAGGGACAGCTGCTG  
GGACCCACCTCCCCCCTTCCCCGGCCACATGCCGCGTCCCTGCCCCCA  
CCCGGGTCTGGTGCTGAGGATACAGCTCTTCTCAGTGTCTGAACAATC  
TCCAAAATTGAAATGTATATTTTTTGCTAGGAGCCCCAGCTTCCTGTGT  
TTTAAATATAAATAGTGTACACAGACTGACGAAACTTTAAATAAATGG  
GAATTAAATATTTAAAAAAAAGCGGCCGCGAATTC

**Fig. 2****SEQ ID NO: 2**

MEQPQEEAPEVREEEEEKEEVAEAEGAPELNGGPQHALPSSSYTDLSRS  
SSPPSLLDQLQMGCDGASCGSLNMECRVCGDKASGFHYGVHACEGCKG  
FFRRTIRMKLEYEKCERSCKIQKKNRNKCYCRFQKCLALGMSHNAIR  
FGRMPEAEKRKLVAGLTANEGSQYNPQVADLKAFSKHIYNAYLKNFNM  
TKKKARSILTGKASHTAPFVIHDIETLWQAEKGLVWKQLVNGLPPYKE  
ISVHVFYRCQCTTVETVRELTEFAKSI PSFSSLFLNDQVTLLKYGVHE  
AIFAMLASIVNKDGLLVANGSGFVTREFLRSLRKPFSDIIEPKFEFAV  
KFNALELDDSDLALFIAAIILCGDRPGLMNVP RVEAIQDTILRALEFH  
LQANHPDAQYLF PKLLQKMADLRQLVTEHAQMMQRIKKTETETSLHPL  
LQEIYKDMY



**Fig. 3**

**SEQ ID NO: 3**

5 ' -CAGTACTGCCGCTTCCAGA-3 '

**Fig. 4**

**SEQ ID NO: 4**

5 ' -CATCCGACCAAAACGGATAG-3 '

**Fig. 5**

**SEQ ID NO: 5**

5 ' -CTGGCACTGGGCATGTCACACAAC-3 ' 

---

24. März 2004

- 1 -

## SEQUENCE LISTING

&lt;110&gt; Bayer HealthCare AG

<120> Diagnostics and Therapeutics for Diseases Associated with  
Peroxisome Proliferator Activated Receptor Delta (PPARD)

&lt;130&gt; BHC 04 01 090

&lt;160&gt; 5

&lt;170&gt; PatentIn version 3.2

&lt;210&gt; 1

&lt;211&gt; 3301

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (2966)..(2972)

&lt;223&gt; n is a, c, g, or t

&lt;400&gt; 1

gaattctg	cgcg	gagcctgc	ggg	gacggc	ggcg	ggttgg	cccc	taggcag	ccg	ggacagt	ggt	60
gtacagt	ggt	ttgggc	atgc	acgtg	atact	cacac	agtgg	cttct	gctca	ccaac	agatg	120
aagac	agatg	cacca	acgag	ggtct	ggaat	ggtct	ggagt	ggtct	ggaaa	gcagg	gtcag	180
ataccc	ctgg	aaaact	gaag	cccgt	ggagc	aatga	tctct	acagg	actgc	ttca	aggctg	240
atggg	aacca	ccctg	tagag	gtccat	ctgc	gttcag	accc	agacg	atgcc	agagc	tatga	300
ctggg	cctgc	aggtg	tggcg	ccgag	ggggag	atcag	ccatg	gagc	agccac	aggag	gaagc	360
ccctg	aggtc	cggga	agagg	aggag	aaaga	ggaag	tggca	gaggc	agaag	gagcc	ccaga	420
gctca	atggg	ggacc	acagc	atgc	acttc	ttcc	agcagc	tacac	agacc	tctcc	cgag	480
ctcct	cgcca	ccctc	actgc	tgg	accaact	gcag	atgggc	tgtg	acgggg	cctc	atgcg	540
cagc	ctcaac	atgg	agtgc	gggt	gtgcg	ggaca	aggca	tcggg	cttc	act	acgg	600
tc	atgcatgt	gaggg	gtgca	agg	gtctct	ccg	tcgtacg	atcc	gcatga	agct	ggagta	660
cg	agaagtgt	gagc	gcagct	gca	agattca	ga	agaagaac	cg	caacaagt	gcc	agtactg	720
cc	gtctccag	aagt	gcctgg	cact	gggcat	gtc	acacaac	gct	atccgt	ttg	gtcggat	780
gcc	ggaggct	gaga	agagga	agct	ggtggc	agg	gtgact	gca	aacgagg	gg	agccagta	840
ca	accacag	gtgg	ccgacc	tga	aggcct	ctcc	aagcac	atct	acaatg	cct	acctgaa	900
aa	acttcaac	atg	acaaaa	aga	aggcccc	cag	catcctc	acc	ggcaaa	ag	ccagccacac	960
gg	cgcccttt	gtg	atccacg	ac	atcgagac	att	gtggcag	gc	agagaagg	gg	ctggtgtg	1020
ga	agcagttg	gtg	aatggcc	tgc	ctcccta	ca	aggagatc	ag	cgtgcacg	tct	tctaccg	1080
ct	gccagtg	acc	acagtg	ag	accgtgcg	gg	agctcact	gag	ttcgcca	ag	agcatccc	1140
cag	cttcagc	ag	ctcttc	tca	acgacca	ggt	taccctt	ct	caagtatg	gc	gtgcacga	1200
gg	ccatcttc	gcc	atgctgg	cct	ctatcgt	ca	acaaggac	ggg	ctgctgg	tag	ccaacgg	1260
cag	tggcttt	gtc	accggtg	ag	ttcctgcg	cag	cctccgc	aa	acccttca	gt	gatatcat	1320
tg	agcctaag	ttt	gaatttg	ctg	tcaagtt	ca	acgccctg	ga	acttgatg	ac	agtgacct	1380
gg	ccctattc	att	gcggcca	tc	attctgtg	tgg	agaccgg	cc	aggcctca	tga	acgttcc	1440
ac	gggtggag	gct	atccagg	ac	accatcct	gc	gtgccctc	ga	attccacc	tgc	aggccaa	1500
cc	accctgat	gcc	cagtacc	tct	tcccaa	gct	gtgcag	aag	atggctg	ac	ctgcggca	1560
act	ggtcacc	gag	caagccc	ag	atgatgca	gc	ggatcaag	aag	accgaaa	cc	gagacctc	1620
gct	gcaccct	ctg	ctccagg	ag	atctacaa	gg	acatgtac	ta	acggcggc	acc	caggcct	1680

```

ccctgcagac tccaatgggg ccagcactgg aggggcccac ccacatgact tttccattga 1740
ccagctctct tccgtgtttt gttgtctccc tctttctcag ttcctctttc ttttctaatt 1800
cctgttgetc tgtttcttcc tttctgtagg tttctctctt cccttctccc ttctcccttg 1860
ccctcccttt ctctctecta tccccacgtc tgtcctcctt tcttattctg tgagatgttt 1920
tgtattattt caccagcagc atagaacagg acctctgctt ttgcacacct tttccccagg 1980
agcagaagag agtgggcctg ccctctgccc catcattgca cctgcaggct taggtcctca 2040
cttctgtctc ctgtcttcag agcaaaagac ttgagccatc caaagaaaca ctaagctctc 2100
tggggcctggg ttccaggga ggctaagcat ggcttgact gactgcagcc ccctatagtc 2160
atgggggtccc tgctgcaaag gacagtggca gaccccgga gtagagccga gatgcctccc 2220
caagactgtc attgcccctc cgatcgtgag gccacccact gacccaatga tctctccag 2280
cagcacacct cagccccact gacaccagt gtccttccat cttcacactg gtttgccagg 2340
ccaatgttgc tgatggcccc tccagcacac acacataagc actgaaatca ctttacctgc 2400
aggcaccatg cacctccctt ccctccctga ggcaggtagg aaccagaga gaggggcctg 2460
caggtagca ggcagggtg ggccaggctt cgggggaggc aggggtcctg caggctcctg 2520
tgggtcagcc cagcacctcg ccagtgga gcttcccggg ataaactgag cctgttcatt 2580
ctgatgtcca tttgtcccaa tagctctact gccctccctt tcccctttac tcagcccagc 2640
tggccaccta gaagtctccc tgcacagcct ctagtgtccg gggacctgtt gggaccagtc 2700
ccacacegct ggtccctgcc ctccctgct ccaggttga ggtgcgctca cctcagagca 2760
gggcaaaagc acagctgggc atgcatgtc tgagcggcgc agagccctcc aggcctgcag 2820
gggcaagggg ctggctggag tctcagagca cagaggtagg agaactggg ttcaagcca 2880
ggcttctctg gtcctgcctg gtcctccctc ccaaggagcc attctatgtg actctgggtg 2940
gaagtgcca gccctgcct gacggnnnnn nngatcactc tctgctggca ggattcttcc 3000
cgctccccac ctaccagct gatgggggtt ggggtgcttc tttcagccaa ggctatgaag 3060
ggacagctgc tgggaccac ctccccctt cccgggccac atgccgcgtc cctgccccca 3120
cccgggtctg gtgctgagga tacagctctt ctgagtgtct gaacaatctc caaaattgaa 3180
atgtatatatt ttgctaggag cccagcttc ctgtgttttt aatataata gtgtacacag 3240
actgacgaaa ctttaaataa atgggaatta aatatttaaa aaaaaagcg gccgcgaatt 3300
c 3301

```

&lt;210&gt; 2

&lt;211&gt; 441

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

Met Glu Gln Pro Gln Glu Glu Ala Pro Glu Val Arg Glu Glu Glu Glu
1          5          10          15
Lys Glu Glu Val Ala Glu Ala Glu Gly Ala Pro Glu Leu Asn Gly Gly
          20          25          30
Pro Gln His Ala Leu Pro Ser Ser Ser Tyr Thr Asp Leu Ser Arg Ser
          35          40          45
Ser Ser Pro Pro Ser Leu Leu Asp Gln Leu Gln Met Gly Cys Asp Gly
          50          55          60
Ala Ser Cys Gly Ser Leu Asn Met Glu Cys Arg Val Cys Gly Asp Lys
65          70          75          80
Ala Ser Gly Phe His Tyr Gly Val His Ala Cys Glu Gly Cys Lys Gly
          85          90          95

```

Phe Phe Arg Arg Thr Ile Arg Met Lys Leu Glu Tyr Glu Lys Cys Glu  
 100 105 110  
 Arg Ser Cys Lys Ile Gln Lys Lys Asn Arg Asn Lys Cys Gln Tyr Cys  
 115 120 125  
 Arg Phe Gln Lys Cys Leu Ala Leu Gly Met Ser His Asn Ala Ile Arg  
 130 135 140  
 Phe Gly Arg Met Pro Glu Ala Glu Lys Arg Lys Leu Val Ala Gly Leu  
 145 150 155 160  
 Thr Ala Asn Glu Gly Ser Gln Tyr Asn Pro Gln Val Ala Asp Leu Lys  
 165 170 175  
 Ala Phe Ser Lys His Ile Tyr Asn Ala Tyr Leu Lys Asn Phe Asn Met  
 180 185 190  
 Thr Lys Lys Lys Ala Arg Ser Ile Leu Thr Gly Lys Ala Ser His Thr  
 195 200 205  
 Ala Pro Phe Val Ile His Asp Ile Glu Thr Leu Trp Gln Ala Glu Lys  
 210 215 220  
 Gly Leu Val Trp Lys Gln Leu Val Asn Gly Leu Pro Pro Tyr Lys Glu  
 225 230 235 240  
 Ile Ser Val His Val Phe Tyr Arg Cys Gln Cys Thr Thr Val Glu Thr  
 245 250 255  
 Val Arg Glu Leu Thr Glu Phe Ala Lys Ser Ile Pro Ser Phe Ser Ser  
 260 265 270  
 Leu Phe Leu Asn Asp Gln Val Thr Leu Leu Lys Tyr Gly Val His Glu  
 275 280 285  
 Ala Ile Phe Ala Met Leu Ala Ser Ile Val Asn Lys Asp Gly Leu Leu  
 290 295 300  
 Val Ala Asn Gly Ser Gly Phe Val Thr Arg Glu Phe Leu Arg Ser Leu  
 305 310 315 320  
 Arg Lys Pro Phe Ser Asp Ile Ile Glu Pro Lys Phe Glu Phe Ala Val  
 325 330 335  
 Lys Phe Asn Ala Leu Glu Leu Asp Asp Ser Asp Leu Ala Leu Phe Ile  
 340 345 350  
 Ala Ala Ile Ile Leu Cys Gly Asp Arg Pro Gly Leu Met Asn Val Pro  
 355 360 365  
 Arg Val Glu Ala Ile Gln Asp Thr Ile Leu Arg Ala Leu Glu Phe His  
 370 375 380  
 Leu Gln Ala Asn His Pro Asp Ala Gln Tyr Leu Phe Pro Lys Leu Leu  
 385 390 395 400  
 Gln Lys Met Ala Asp Leu Arg Gln Leu Val Thr Glu His Ala Gln Met  
 405 410 415  
 Met Gln Arg Ile Lys Lys Thr Glu Thr Glu Thr Ser Leu His Pro Leu  
 420 425 430  
 Leu Gln Glu Ile Tyr Lys Asp Met Tyr  
 435 440



<211> 19  
<212> DNA  
<213> artificial sequence  
<220>  
<223> forward primer  
<400> 3  
cagtactgcc gcttccaga 19  
<210> 4  
<211> 20  
<212> DNA  
<213> artificial sequence  
<220>  
<223> reverse primer  
<400> 4  
catccgacca aaacggatag 20  
<210> 5  
<211> 24  
<212> DNA  
<213> artificial sequence  
<220>  
<223> probe  
-----  
<400> 5  
ctggcactgg gcatgtcaca caac 24